CN1668749A - 在cho细胞内表达重组蛋白的方法 - Google Patents
在cho细胞内表达重组蛋白的方法 Download PDFInfo
- Publication number
- CN1668749A CN1668749A CNA038169142A CN03816914A CN1668749A CN 1668749 A CN1668749 A CN 1668749A CN A038169142 A CNA038169142 A CN A038169142A CN 03816914 A CN03816914 A CN 03816914A CN 1668749 A CN1668749 A CN 1668749A
- Authority
- CN
- China
- Prior art keywords
- promotor
- chinese hamster
- hamster ovary
- transfection
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 21
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title claims abstract description 12
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title claims abstract description 12
- 210000004978 chinese hamster ovary cell Anatomy 0.000 title abstract description 7
- 239000013604 expression vector Substances 0.000 claims abstract description 30
- 108090000623 proteins and genes Proteins 0.000 claims description 57
- 108020002326 glutamine synthetase Proteins 0.000 claims description 54
- 102000005396 glutamine synthetase Human genes 0.000 claims description 53
- 230000014509 gene expression Effects 0.000 claims description 51
- 238000001890 transfection Methods 0.000 claims description 47
- 241000699802 Cricetulus griseus Species 0.000 claims description 40
- 210000001672 ovary Anatomy 0.000 claims description 40
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 claims description 37
- 230000033228 biological regulation Effects 0.000 claims description 19
- 239000003550 marker Substances 0.000 claims description 19
- 108060003951 Immunoglobulin Proteins 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 16
- 102000018358 immunoglobulin Human genes 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 230000002103 transcriptional effect Effects 0.000 claims description 15
- 241000700605 Viruses Species 0.000 claims description 6
- 241001529936 Murinae Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 80
- 239000000047 product Substances 0.000 description 29
- 229940027941 immunoglobulin g Drugs 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 24
- 239000005090 green fluorescent protein Substances 0.000 description 23
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 19
- 239000012634 fragment Substances 0.000 description 18
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 17
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 11
- 230000008685 targeting Effects 0.000 description 11
- 238000003146 transient transfection Methods 0.000 description 11
- 238000012163 sequencing technique Methods 0.000 description 10
- 239000006052 feed supplement Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 238000003153 stable transfection Methods 0.000 description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 238000004520 electroporation Methods 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 230000008521 reorganization Effects 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 238000004321 preservation Methods 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000699800 Cricetinae Species 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 108010077544 Chromatin Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 210000003483 chromatin Anatomy 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 241001505967 Cricetinae gen. sp. Species 0.000 description 4
- 230000004544 DNA amplification Effects 0.000 description 4
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 102000013275 Somatomedins Human genes 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 102000004338 Transferrin Human genes 0.000 description 4
- 108090000901 Transferrin Proteins 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 238000013467 fragmentation Methods 0.000 description 4
- 238000006062 fragmentation reaction Methods 0.000 description 4
- 229960002989 glutamic acid Drugs 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 238000001638 lipofection Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000012581 transferrin Substances 0.000 description 4
- 230000010474 transient expression Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000003151 transfection method Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108700002232 Immediate-Early Genes Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108700007696 Tetrahydrofolate Dehydrogenase Proteins 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 238000002708 random mutagenesis Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102100021210 Double homeobox protein B Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- KGWDUNBJIMUFAP-KVVVOXFISA-N Ethanolamine Oleate Chemical compound NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O KGWDUNBJIMUFAP-KVVVOXFISA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 101150074355 GS gene Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000968521 Homo sapiens Double homeobox protein B Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 108700012441 IGF2 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 1
- 108020005210 Integrons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000701029 Murid betaherpesvirus 1 Species 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 239000000589 Siderophore Substances 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 1
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 1
- 230000010632 Transcription Factor Activity Effects 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- -1 Xie Ansuan Chemical compound 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000001399 anti-metabolic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000037011 constitutive activity Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 108010025964 lipophorin Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000010363 phase shift Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 150000004788 tropolones Chemical class 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
一种用包含鼠IgG 2A基因座的表达载体在CHO细胞内表达重组蛋白的方法。
Description
本发明涉及在CHO细胞系内表达重组产物基因的方法,涉及重组CHO细胞系,还涉及新的表达载体构建物。
中国仓鼠卵巢细胞(CHO)哺乳动物表达系统被广泛用于生产重组蛋白。除了诸如杂交瘤细胞系等淋巴细胞系之外,它是极少数能够简单而有效地进行高密度动物细胞悬浮培养的细胞系之一。而且,它们的产品得率非常高,抗代谢压力能力较强,淋巴细胞则较难进行产业规模的培养。考虑到生产成本,这对于获得生物反应器每轮运行的蛋白最大得率来说至关重要。培养基组成的选择,生物反应器的设计和操作这些参数影响着得率,但其优化十分复杂。增强调控蛋白质表达的启动子的强度和转录活性更有可能提高得率。在静止期以106至107细胞/毫升的细胞密度进行基因表达的高密度或补料分批批培养中,单细胞表达水平的增长将转化为相当可观的得率增长。
US5,866,359描述了一种在CHO细胞和NSO细胞内通过弱启动子与腺病毒E1A的共表达来增强本已很强的hCMV启动子的表达。E1A是一种多功能转录因子,作用于细胞周期调节,同时具有独立转录活化结构域和抑制功能结构域。将E1A表达水平精调到较低水平是实现基因的反式激活和避免对细胞周期进展造成不利影响之间理想平衡的关键。除了需要仔细选择启动子驱动的E1A表达之外,该系统的缺点还在于部分抑制E1A表达细胞的蛋白质合成能力而不是目标重组蛋白的表达。
WO95/17516在B细胞系的淋巴细胞例如广泛使用的NSO骨髓瘤内用鼠免疫球蛋白γ2A基因座将表达载体构建物导向高活性基因座。NSO细胞是一种鼠浆细胞或B细胞肿瘤细胞系。唯有在B细胞内,还该免疫球蛋白基因座的染色质才处于完全活化且开放的状态,才允许整合于这些基因座中的天然免疫球蛋白启动子或重组表达构建物表现出高转录活性。
其缺点在于,由于同源重组原则,只有在含有该重组热点的γ2A导向序列相匹配的鼠细胞系内,导向序列才能有效定向;要获得高水平的表达,γ2A基因座区必需是一个基因转录活跃区,这限制了导向序列与B细胞类细胞同源重组的有效性。
本发明的目标在于提供一种适合CHO蛋白表达的表达系统,该系统能够增强标准启动子的表达。根据本发明,为CHO细胞的表达载体配备一段原用于在鼠B细胞内同源重组的基因导向序列出人意料地实现了这一目标。
附图显示了本发明几种可能的实施方式。其中:
图1:CHO-K1细胞瞬时转染中,hCMV启动子和hCMV启动子在IgG 2A热点序列存在下的绿荧光蛋白(GFP)相对表达水平。
图2:稳定转染的CHO-K1细胞内,hCMV启动子和hCMV启动子在IgG 2A热点序列存在下的GFP相对表达水平。
图3:带有IgG 2A导向序列的hCMV-MIE表达载体的质粒图谱。
根据本发明,一段用于在哺乳动物细胞内表达重组基因的DNA序列包含重组产物基因和调控该产物基因表达的启动子,以CMV启动子为佳,还包含能够增强启动子所调控表达的鼠免疫球蛋白γ2A基因座DNA序列或其片段或其序列变体。根据本发明,这样的DNA序列可用于构建在CHO细胞内表达重组产物的表达载体。
根据本发明,重组蛋白质的表达包括以下步骤:
a.培养以表达载体转染的CHO细胞,该表达载体含有能在CHO细胞内驱动重组蛋白表达的启动子和能够增强所述启动子活性的鼠IgG 2A基因座DNA或其序列变体或其片段,和
b.收获产物蛋白。
本发明的重组产物指希望大量表达和收获的产物蛋白。它可以是各种感兴趣的蛋白质,例如白介素之类治疗用蛋白质,酶,或抗体等多聚体蛋白的亚基,或它们的片段。重组产物基因可包含一段信号序列,其编码的序列令表达的多肽向宿主生产细胞外分泌。本发明另一优选实施方式中,所述产物蛋白是分泌蛋白。更好的是,第一蛋白或产物蛋白是抗体或基因工程抗体或其片段,最好是免疫球蛋白G(IgG)抗体。
鼠免疫球蛋白γ2A基因座(IgG 2A)的DNA序列最早在WO95/17516中被设计用作基因组导向序列用于产生高表达重组产物的稳定重组B淋巴细胞系。B淋巴细胞或浆细胞一般以极高的水平表达Ig重链基因座的免疫球蛋白RNA,这可能是因为其细胞类型特异性启动子/转录因子活性和开放式染色质结构。本发明优选的鼠免疫球蛋白γ2A基因序列与WO95/17516所用的导向序列相同。这是一段5.1kb的BamHI基因组片段,包括除CH1外显子最5’部分之外全部的鼠Igγ 2A编码区(Yamawaki-Kataoka,Y.等,美国科学院学报(1982)79:2623-2627;Hall,B等,分子免疫学(1989)26:819-826;Yamawaki-Kataoka,Y.等,核酸研究(1981)9:1365-1381)。根据本发明,促进定点同源重组不是相关的免疫球蛋白γ2A(IgG 2A)基因特性。因此,所述IgG 2A基因序列的各种变体或其片段或变体的片段,如果在CHO细胞内瞬时表达或稳定表达条件下都能够增强重组产物基因在启动子例如优选的hCMV启动子调控下的表达,则都在本发明范围之内。
这样,“功能性”变体包括例如碱基的插入、缺失或点突变,并可用本领域熟知的方法来产生,例如引物引导的PCR,“易错”PCR,“基因改组(gene-shuffling)”PCR即通过PCR将交叠的DNA片段进行重新组合,或者先对细菌克隆进行体内随机诱变然后在CHO细胞内进行基因库转染和功能选择。例如,随机诱变可按照Miller,J.,的《分子遗传学实验》(冷泉港,1972)所述用烷基化剂或UV-辐照进行。或者,还可以采用宿主菌的天然突变株。
在DNA序列中,这样的变体序列或序列片段与天然免疫球蛋白γ2A基因座相应部分的序列同源性至少为65%,至少75%为佳,至少90%最好。例如,可以在位于膜外显子2(M2)上游39bp处的天然StuI位点插入一个SalI限制位点作为鼠免疫球蛋白γ2A序列内一个独特的线性化位点;这样的序列变体最初被设计用于定点重组导向,但也可用于本发明目的。
“启动子”指引导RNA聚合酶与DNA结合并启动RNA合成的一段DNA序列。本发明的启动子是在CHO细胞内有活性的启动子。这样的启动子最好是强启动子。强启动子指在CHO-KI细胞内引发mRNA合成的频率等于或高于hCMV核心启动子/增强子片段(US5168062)的启动子。这样的启动子可以是例如US5589392所述的细胞类型依赖性启动子,但更好的是通用强启动子,尤其是组成型活性的病毒启动子,例如SV40病毒的早期或晚期启动子,人或鼠巨细胞病毒(mCMV或hCMV)的立即早期启动子,单纯性疱疹病毒的胸苷激酶(TK)启动子,Rous肉瘤病毒长末端重复启动子(RS-LTR),尤其好的是US5,385,839和/或EP-323997-A1所述的呈2.1kb PstI片段的hCMV-MIE启动子。EP-323 997-A1所述的带有hCMV主要立即早期(MIE)基因的完整首个功能性内含子的hCMV启动子尤为本发明实施方式所优选。
用于本发明的hCMV启动子在其上游/增强子部分最好没有“调节子(modulator)”序列部分。已发现,“调节子”序列对hCMV启动子在CHO细胞内的活性不利,该序列从MIE转录起始位点-750bp处延伸至-1150bp(Meier等,1996,Intervirology39:331-342,“hCMV立即早期基因表达的调控”),在瞬时转染中尤其不利。没有调节子序列的IgG 2A热点序列(无调节子或缩写为mod-)对hCMV启动子的增强效应甚至更明显。
瞬时转染的特征在于不对载体所带的选择标记施加任何选择压力。瞬时转染所得的是一混合细胞群,其中既有摄取了外源DNA并能够表达的细胞也有没有摄取外源DNA的细胞。那些表达外源表达盒的细胞常常还没有将转染的DNA整合到基因组内,因而容易丢失外源DNA,而且其在瞬时转染细胞群培养物中的生长优于转染细胞。所以,刚转染后的表达最强,而后逐渐减弱。较好的是,将本发明所述的瞬时转染子理解为能够在转染后,在无选择压力的条件下,在细胞培养物中维持90小时的细胞。
较好的是,本发明的转染CHO宿主细胞是稳定转染的细胞,尤其是就前述hCMV启动子而言。稳定转染即新引入的外源DNA通过随机非同源重组被整合到基因组DNA内;就载体序列而言,本发明所述的稳定转染可能丢失与重组产物基因表达非直接相关的部分载体序列,例如在基因组整合后成为多余的细菌拷贝数控制区。转染细胞至少向基因组内整合了表达载体的一部分或多个不同部分。类似的,本发明所述的转染宿主细胞还包括用两个或数个DNA序列转染CHO细胞从而至少在体内形成本发明表达载体必需元件的功能性对等物,即合适的启动子和IgG 2A热点序列调控下的产物基因。关于DNA片段转染后功能性DNA序列的体内装配可参见例如WO99/53046。如果进一步受到为基因扩增而施加的选择压力,这样的稳定整合可能会在CHO细胞内形成双微染色体。这也属于本发明所述的“稳定”。本发明表达载体随机整合到CHO细胞基因组内后,导向序列将增强启动子促进重组产物蛋白表达的活性。这一效应是无法基于成熟鼠B细胞系例如浆细胞瘤(plasmacytoma)骨髓瘤细胞系内的同源基因定向所实现或预见的;在那样的定向中,IgG 2A导向序列的作用仅限于提高高得率同源整合子(integrants)的频率,因为IgG 2A基因座是一重组“热点”。如上所述,在合适的目标B细胞内,免疫球蛋白基因组区的染色质处于开放的高活性状态。
“表达载体”指转染后mRNA在合适的哺乳动物宿主细胞内转录和翻译所必需的DNA序列。正确构建的表达载体通常应包含:至少一个可在动物细胞中表达的选择标记,用于插入重组产物基因的表达盒使其处于上游启动子区调控之下的数量有限的有用的限制位点。如果仅用于瞬时/游离型表达,表达载体还可以包含一个复制起点,例如Eppstein Barr病毒(EBV)或SV40病毒的复制起点,用于在真核细胞宿主内自我复制/游离型维持,但可以没有选择性标记。表达载体例如但不限于线性DNA片段,包含细胞核定向序列或针对与转染剂之间的相互作用而进行了优化的DNA片段,动物病毒或可以在细菌之间穿梭和复制的合适的质粒。可以采用各种常用选择标记,例如胸苷激酶(tk),二氢叶酸还原酶(DHFR)或谷氨酰胺合成酶(GS)。优选实施方式之一采用了可表达的GS选择标记(Bebbington等,1992,“以谷氨酰胺合成酶基因作为可扩增选择标记,重组抗体在骨髓瘤细胞中的高水平表达”,Bio/Technology10:169-175;Cockett等,1990,“利用谷氨酰胺合成酶基因扩增,金属蛋白酶组织抑制剂在中国仓鼠卵巢(CHO)细胞内的高水平表达”,Bio/Technology8:662-667)。GS系统是仅有的两种对治疗用蛋白质生产来说特别重要的系统之一。与二氢叶酸还原酶(DHFR)系统相比,GS系统在生长过程中具有很大的时间优势,因为该系统一般可由最初的转染子形成高产细胞系,这样就不必通过不断提高选择试剂浓度的多轮选择来实现基因扩增(Brown等,1992,“用谷氨酰胺合成酶(GS)系统生产重组抗体的方法的发展”,Cytotechnology9:231-236)。不用说,与采用表达标记基因的第二转录单元等效的是:利用例如常用的内部核糖体进入位点,一个表达单元可以用一个单顺反子表达盒同时表达产物基因和标记基因。反之,本发明的热点IgG 2A序列和包含启动子和/或标记盒的表达盒不一定要在同一表达载体上顺式运作;上述元件可以由共转染的不同载体或DNA片段携带,然后在染色体上唯一的串联整合位点进行整合。
本发明的另一目的是提供用本发明DNA序列转染的CHO宿主细胞。其它目的还包括转染此类宿主细胞的方法和在此类宿主细胞内表达重组产物基因的方法。本发明说明书中对优选实施方式的解说和引用同样适用于以上所述本发明的其它目的。需要指出的是,用本发明DNA序列或载体转染的宿主细胞应理解为瞬时转染或稳定转染的细胞系。本发明可根据宿主细胞类型选用各种转染技术,例如本领域熟知的电穿孔、磷酸钙沉淀、DEAE-葡聚糖转染、脂质转染等。
合适的宿主细胞系可以是各种中国仓鼠卵巢(CHO)细胞系(Puck等,1958,试验医学杂质108:945-955)。“宿主细胞”指能在培养物中生产并表达所需的重组蛋白质产物的细胞。合适的细胞系可以是例如CHO KI(ATCC CCL-61),CHOpro-3,CHO DG44,CHO P12或dhfr-CHO细胞系DUK-BII(Chassin等,PNAS77,1980,4216-4220)或DUXB 11(Simonsen等,PNAS80,1983,2495-2499)。在CHO细胞中,免疫球蛋白基因的基因座是不活跃的,因而染色质处于紧密包装(packaged)或闭合状态。这样,由于染色质的这种特殊状态,整合到免疫球蛋白基因座内的任何基因构建物都不能高水平地表达重组蛋白,除非该构建物自带能够开启染色质中该表达盒两侧的旁侧基因座调控区。而且,免疫球蛋白基因序列,尤其是其内含子部分,表现出相当的种间差异,例如在小鼠和仓鼠之间的差异。免疫球蛋白基因座的启动子或增强子元件都是种特异性且组织特异性的,而且只在B细胞内具有活性。各种天然免疫球蛋白启动子可产物编码完整IgG重链的全长转录产物,本发明鼠IgG 2A序列即使没有这样的天然启动子存在仍然能够在CHO细胞内增强基因的表达。较好的是,本发明IgG 2A序列没有这样的启动子。出人意料的是,用本发明表达载体瞬时转染CHO细胞后,鼠IgG 2A导向序列甚至增强了CHO细胞内的基因表达(图1);这样的瞬时表达是本发明方法的又一优选实施方式。一般发生在转染后20-50小时的瞬时表达试验中,转染载体一直是染色体外元件,没有整合到基因组内。
适合哺乳动物细胞系的培养基和培养方法是本领域众所周知的,可参见例如US5633162。用于实验室锥瓶培养或低密度细胞培养并根据不同细胞类型的需要而进行了改进的标准细胞培养基有例如:Roswell Park Memorial Institute(RPMI)1640培养基(Morre,G.,美国医学协会杂志,199,p.519 f.1967),L-15培养基(Leibovitz,A.等,美国卫生杂志,78,1p.173 ff.1963),Dulbecco’s改进的Eagle’s培养基(DMEM),Eagle’s基本必需培养基(MEM),Ham’s F12培养基(Ham,R.等,美国科学院学报53,p288 ff.1965)或Iscoves’s改进的无白蛋白、运铁蛋白和卵磷脂的DMEM(Iscoves等,试验医学杂志1,p.923 ff.,1978)。例如,Hams’s F10或F12培养基是专门为CHO细胞培养设计的。其它适合CHO细胞的培养基可参见EP-481 791。已知,可在这样的培养基内补加胎牛血清(FBS,又称FCS),从而提供激素和生长因子的充沛的天然来源。动物细胞培养现在已经是一种常规操作,在科教课本和手册中有详尽的描述,例如,在R.Ian Fresney,《动物细胞培养手册》第4版(Wiley-Liss/N.Y.,2000)有详细的记载。
较好的是,本发明的细胞培养基不含胎牛血清(FBS或FCS),可称为“无血清”。在无血清培养基中,细胞一般需要胰岛素和运铁蛋白以达到最佳生长状态。至少部分运铁蛋白可以用非肽类螯合剂或WO94/02592所述的环庚三烯酚酮等铁载体取代,或通过提高某种有机铁的含量并最好配以抗氧化剂例如维生素C来取代。大多数细胞系需要一种或多种合成生长因子(包含重组多肽),包括例如表皮生长因子(EGF),成纤维细胞生长因子(FGF),胰岛素样生长因子I和II(IGFI,IGFII)等。可能需要的其它因子还包括:前列腺素,转运和结合蛋白(例如血浆铜蓝蛋白,高密度和低密度载脂蛋白,牛血清白蛋白(BSA)),激素,包括甾体类激素,以及脂肪酸。多肽因子试验最好按步骤进行,即在已知促生长多肽存在下测试新的多肽因子。那些生长因子是合成或重组的。在动物培养方面有多种方法,其中之一如下所述。首先需确定细胞从加血清培养基中转移过来后能够存活和/或缓慢生长3-6天的条件。对大多数细胞类型来说,这至少部分取决于接种密度。一旦找到了最适的激素/生长因子/多肽补剂就可降低存活所需的接种密度。在一更好的实施方式中,细胞培养基不含蛋白质,即没有胎牛血清和各种蛋白质生长因子补剂或诸如重组运铁蛋白之类其它蛋白质。
本发明方法即重组蛋白表达和收获的一种可能的实施方式是动物宿主细胞在例如工业分批生物反应器内的高密度生长。然后可进行传统的下游加工。为此,必需采用高密度生长培养基。此类高密度生长培养基通常可补充以全氨基酸等营养素,前述含量的葡萄糖之类能源,无机盐,维生素,微量元素(即最终浓度以微摩尔计的无机化合物),缓冲剂,四种核苷或相应的核苷酸,(还原态)谷胱苷肽、维生素C等抗氧化剂,以及其它重要成分,例如重要的膜脂类,例如胆固醇或磷酯酰胆碱,或脂类前体,例如胆碱或肌醇。高密度培养基中上述化合物中的大多数或全部被增浓(强化),使得它们的含量高于前述标准培养基,将GB2251249与RPMI1640相比既可看出这一点,但是作为渗透压调节基准的无机盐没有被增浓。较好的是,本发明的高密度培养基中完全氨基酸除色氨酸外都被均衡强化,含量超过每升培养基75mg。较好的是,在达到氨基酸总体要求之外,谷氨酰胺和/或天冬酰胺的含量超过1g/L,超过2g/L更好。本发明中,高密度细胞培养物指动物细胞群中活细胞的即时密度至少为105个/毫升,至少106个/毫升更好,该集群由单细胞或低活细胞密度的接种物在恒量或递增量的培养基中连续配以而得。
更好的实施方式中,分批培养物是一个培养物系统,其中,如GB2251249所述,在通过分批补料来控制葡萄糖浓度之外,至少向细胞培养物中补加谷氨酰胺,或者还有一种或数种其它氨基酸(优选甘氨酸)以保持它们在培养基中的浓度。更好的是,将谷氨酰胺或许还有一种或数种其它氨基酸的补加与一种或多种能源例如葡萄糖的补加相结合,如EP-229809A所述。首次补料一般在培养开始后25-60小时;例如,可以在细胞密度达到106个/毫升左右时开始加料。众所周知,在培养的动物细胞中,“谷氨酰胺分解”(McKeehan等,1984,“动物细胞中的谷氨酰胺分解”,培养细胞中的糖代谢,M.J.Morgan编辑,Plenum出版社,纽约,pp.11-150)可能成为生长期的重要能源。补加谷氨酰胺和/或天冬酰胺(关于用天冬酰胺替代谷氨酰胺可参见Kurano,N等,1990,生物技术杂志15,113-128)的总量一般为0.5-10g/L培养物,以1-2g/L为佳;补料中可以包含的其它氨基酸的总补料量为10-300mg/L培养物,具体地说,甘氨酸、赖氨酸、精氨酸、缬氨酸、异亮氨酸和亮氨酸的补料量可以相对较高,至少150-200mg。所述补料可以是间歇式添加(shot-addition)或连续泵送添加,优选几乎连续地向生物反应器泵送补料。不用说,在分批培养过程中,通过加碱或缓冲剂,生物反应器内的pH被精心调控为最适合给定细胞系的生理pH。用葡萄糖作为能源时,总葡萄糖补料量一般为1-10g/L培养物,以3-6g/L为佳。补料中除氨基酸外最好还含有少量例如5-20mg/L培养物的胆碱。更好的是,胆碱的补加与乙醇胺的补加相结合,就象US6048728所述,尤其是同时补加谷氨酰胺的时候。不用说,如果采用GS-标记系统,谷氨酰胺的需量低于非GS-标记系统,内源性产生的谷氨酰胺之外过量谷氨酰胺的累积会产生氨和中毒。对GS来说,培养基或补料中的谷氨酰胺一般可用它的对等物和/或前体代替,即用天冬酰胺和/或谷氨酸。
本发明的另一个目的在于设计一种表达载体,它包含至少一个(第一)产物基因转录单元,该单元在宿主细胞内表达后即产生蛋白质,而且该单元受小鼠巨细胞病毒启动子(mCMV启动子)调控,还包含一个第二转录单元,该单元包含谷氨酰胺合成酶(GS)标记基因。所述产物基因,或称之为感兴趣基因(GOI),可以是例如免疫球蛋白编码序列。谷氨酰胺合成酶标记基因是编码具有酶活性的GS的序列,包括天然序列或其变体。前文关于“功能性变体”的定义,包括序列同源性优选范围,同样适用于此。较好的是,所述GS标记基因是一哺乳动物GS标记基因或其衍生物。出人意料的是,与第一转录单元中感兴趣基因受hCMV启动子调控的表达载体相比,这样的载体进入CHO细胞的转染率高得多。这并非因为mCMV启动子在CHO细胞内的转录活性比mCMV启动子高得多;通常认为,转染后,较高的代谢负荷会降低克隆的存活率,导致转染子较少。这样,不能简单地将这一效果与所表达蛋白质产物的量或意料之外的不利于转染子生长的毒性相关联。实际上,以上发现大大出乎本领域技术人员的预料。
本发明的其它目的包括以表达载体转染的动物宿主细胞尤其是CHO细胞和相关转染方法,所述载体可以保持处于染色体外,也可稳定地整合到基因组内。同样,用两个或更多个基因片段转染动物细胞尤其是CHO细胞,这多个基因片段体内形成作为本发明目标的转录单元的功能对等物,这也包括在转染的宿主细胞这一定义之中。较好的是,所述宿主细胞是稳定转染的细胞,即第一和第二转录单元都整合到染色体内。
本发明的另一目的是提供mCMV启动子用于提高在CHO细胞内转染率的用途,优选用如下表达载体进行的转染:该表达载体包含至少一个第一产物基因转录单元,该单元在宿主细胞内表达后即产生蛋白质,而且该单元受小鼠巨细胞病毒启动子(mCMV启动子)调控,还包含一个第二转录单元,该单元包含谷氨酰胺合成酶(GS)标记基因。所述第一和第二表达序列由不同的载体携带,或者作为分处不同表达单元中的基因片段。而且,可以用带有mCMV的第一转录单元转染表达GS的已重组CHO细胞。根据本发明,“提高转染率”通过在相同转染条件和相同细胞培养条件下,对相同宿主细胞,将mCMV启动子和本发明表达载体存在下的转染率与相同表达载体中mCMV被换以US5658759所述和本发明SEQID NO:3所示hCMV-第一内含子增强子/启动子构建物的转染率相比较来定义。对于给定的相同产物基因,该hCMV-内含子MIE-启动子构建物是测定转染率增强效果的参照标准。较好的是,mCMV可将转染率提高至少10倍。
以上定义都同样适用于本发明的各项目的。需要强调的是,鼠IgG 2A导向序列并不是实现本发明目标的前提。
鼠细胞巨噬病毒(mCMV)是高度多样性的疱疹病毒科的一员。即使是不同宿主的巨噬细胞病毒之间也可能存在显著差异。例如,mCMV与人巨噬细胞病毒(hCMV)在生物学特性、立即早期(IE)基因组织和总体核酸序列上都存在相当大的差异。而且,235kbp的mCMV没有hCMV特征性的内部重复序列和末端重复序列。所以,mCMV基因组没有异构体(Ebeling,A等,1983,病毒学杂志47,421-433;Mercer J.A.等,(1983),病毒学129,94-126)。根据本发明,可以利用基本对应于US4968615所述约2.1kb PstI片段的启动子区或其功能性片段。更好的实施方式中,所用的cMCV启动子片段包含转录起始点(+0)至此前-500bp序列。出人意料的是,这一片段驱动的表达比自-500bp再向前多800bp的启动子盒更强。在最好的实施方式中使用的是启动子核心区,即自转录起始点至上游-150bp左右处的Xho I限制位点,甚至从天然转录起始点至上游-100bp的序列。不用说,为了包含合适的限制位点以便插入重组产物基因,可以人工改造转录起始点。
根据本发明,受mCMV启动子调控的第一转录单元可以包含至少一段内含子序列。这一做法是本领域的常识,是为了稳定RNA转录产物以提高由相应的mRNA合成蛋白质的效率。但是,为了蛋白质合成的效率,不考虑对转染率的影响,不建议在mCMV启动子构建物内包含mCVM的天然内含子。与hCMV启动子的情形(US5591639)相反,这样的mCMV第一内含子会降低mCMV启动子下重组基因的表达,所以不是优选实施方式。
序列表给出了GS标记基因盒的优选、可能实施方式。SEQ ID NO:1(pEE15.1hCMV/GFP+热点)和SEQ ID NO:2(pEE14.4 hCMV/GFP)是适宜的SV40(早、晚)启动子调控的GS基因盒范例,这是一个中等偏弱启动子,序列中还包含一个hCMV启动子调控下的GFP(绿荧光蛋白)表达盒。SEQ ID NO:1是SV40早期启动子调控下的GS cDNA序列,有关其细节详见附图3。SEQ ID NO:2一人造GS小基因盒,其中包含一个SV40晚期启动子调控下的内含子。CHO细胞不是天然谷氨酰胺营养缺陷型的,所以可以进行Cockett等所述的选择方案(1990,“利用谷氨酰胺合成酶基因扩增在中国仓鼠卵巢(CHO)细胞内高表达金属蛋白酶的组织抑制剂”,Bio/Technology8:662-667)。该文献还例举了适合CHO细胞的转染方法:例如,可以采用经典的磷酸钙沉淀法或较新的脂质转染技术。转染率一般定义为受转染细胞群中转染阳性细胞(瞬时转染)或克隆(选择期后的稳定转染)的数量。本发明的效果可以通过例如用脂质转染法(任意市售试剂和生产商的说明书)以包含SEQ ID NO:3(pEE12.4 hCMV-GFP+SV 40早期启动子/GS cDNA)或SEQ IDNO:4(pEE12.4 mCMV-GFP+SV 40早期启动子/GS cDNA)的质粒转染CHO-K1细胞来展现。可将转染后细胞培养在各种常规培养基中。这些培养基可以是前述含血清培养基或无血清培养基。较好的是含血清培养基,尤其是补充了至少1%(v/v)胎血清,最好是至少5%(v/v)胎血清,例如胎牛血清。另一优选实施方式采用电穿孔转染法。
实施例
实验1
包含热点序列的GFP载体在CHO-K1内的瞬时表达和稳定表达
CHO-K1细胞(ATCC CCL-6)在含10%FCS的普通细胞培养基(GMEM-S)中适应和培养。为了进行GS选择,培养基必须完全不含谷氨酰胺,如后文表1所示;因此必需使用经透析FCS。培养均为36.5℃、125rpm的摇瓶培养。采用脂质转染(SuperfectinTM,Gibco,UK),转染子细胞群的绿荧光在FACS中用488nm激发波长测定。对每一种GS/GFP载体构建物,各进行5次转染,所有数据都是分析5个独立细胞群所得的平均值。从转染后48小时的瞬时转染子开始,挑选细胞数vs.荧光度图中表达水平为最高值10%的活细胞来确定平均荧光度(图1)。通过在正向vs.侧向散射图(Forward vs.Sideward scatter diagram)中通过门控(gating)挑选出活细胞群。
为了产生稳定转染子,转染后24小时,在无谷氨酰胺培养基中添加25μMMSX(甲硫氨酸sulphoximine,Crockett等,ibd.),继续培养且定期分割培养物,持续26天,如此选择GS标记。观察其它氨基酸水平的中值对于MSX选择强度的影响,参见Bebbington等,US5827739。然后如上所述进行荧光度分析(图2)。
以非转染细胞作为阴性对照。SEQ ID NO:1展示了热点载体(pEE15.1’hCMV+热点),它驱动GFP在hCMV启动子调控下的表达,该启动子含有完整的CMV第一内含子,该载体实际上就是图3所示的pEE15.1载体内多接头区的Eco RI限制位点插入了GFP序列。对应于SEQ ID NO:3的pEE 12.4‘hCMV与pEE 15.1’hCMV+热点的区别仅在于不含内有IgG 2A序列的5.1kb的Bam H1片段。将pEE 12.4作为载体对照。另一个载体对照是pEE 12.4‘hCMV(Kozak-)’,是通过引物引导的诱变(Sambrook等,《分子克隆》,冷泉港,1983)将与翻译起始点重合的克隆位点的Kozak序列(GCCGCCACCATGG)移码突变为功能性Kozak序列(ACC
AT
GGT
CCATGG)而形成的,由此消除了原先的Kozak翻译起始点。SEQID NO:1所示的载体被进一步删除hCMV增强子部分400bp的调节子区,删除转录起点上游-750bp处的增强子元件,由此形成pEE 15.1‘hCMV(mod-)/GS cDNA’。如图2所示,将pEE 15.1(图3)的GS cDNA盒换作SEQ ID NO:2所示的pEE 14.4‘hCMV(mod-)/GFP的GS(小基因),形成pEE 15.1‘hCMV(mod-)/GS小基因。这样,所有被转染细胞都含有包含GFP编码序列的质粒载体。GS小基因含有单个GS基因的第一内含子和一段约1kb的3’侧翼DNA,处于SV40晚期启动子调控下;据信,基因组GS DNA的3’部分可提高载体DNA的拷贝数,因而可提高被转染细胞内的GS含量(见US4770359,Bebbington等)。虽然本发明的所用的hCMV载体都表达GS cDNA序列中的GS标记基因,仍使用GS小基因作为又一对照来排除GS拷贝数和表达水平可能造成的影响。
为了分析稳定转染的GHO细胞的产生和表达,用线性化的热点载体pEE 15.1‘hCMV+热点’载体进行转染。Sal I线性化质粒在含IgG 2A的序列部分被切断,游离的DNA末端可能促进基因组区域的重组,所述基因组区域的两侧DNA需与所述末端具有一定程度同源性,由此可测试鼠IgG 2A在CHO细胞内可能具有的定向效果。Pvu I切断在细菌内酰胺酶标记基因内,因而能够促进异源随机重组。实际上,Pvu I线性化转染子内的荧光度较高,说明载体线性化有一定的影响,而且CHO细胞内向免疫球蛋白基因座的定向不能解释本发明的效果。此外,在瞬时转染细胞群中也一样观察到启动子活性增强与各个载体构建物的相对强度密切相关。显然,在转染早期没有发生基因组整合。
图3显示了约12830bp的载体pEE 15.1。有关GS标记和hCMV-p/内含子表达盒的详细描述可参见US5827739和US5591639。pEE 15.1是本发明表达载体的一种可能实施方式,但其多接头位点中没有插入编码重组产物蛋白的DNA序列。SEQ ID NO:1展示了含有GFP的pEE 15.1构建物全部13535bp的序列:其中,GFP编码序列插在读码框内的Eco RI限制位点,该位点位于中部的12814碱基处;该独特限制位点含有ATG起始密码并优化了起始密码的Kozak序列环境,其详述可参见US5591639。这样,GFP蛋白表达就处于hCMV-重要立即早期基因启动子(hCMF-MIE或简写为hCMV)调控下,其后则紧接hCMV-MIE基因的第一内含子,再后面是Nco I位点(见US5591639)。多接头区下游的SV40聚A位点确保了聚腺苷酸化的完成。pEE 15.1还含有一段编码仓鼠谷氨酰胺合成酶(GS)的cDNA序列,该序列受SV40早期启动子调控,其后是SV40内含子+聚A序列。IgG 2A基因座或“热点”序列(阴影框CH1,Hi,CH2,CH3,M1和M2代表重链恒区,铰链区,细胞膜锚定区)即WO9517516及其参考文献中所述的鼠IgG 2A基因座的5.1kb BamH I片段。图中显示了独特的Pvu I和Sal I限制位点。
实验2
用电穿孔法以mCMV p12.4-GFP构建物(SEQ ID NO:4)转染CHO细胞
将附壁CHO-K1细胞(ATCC CCL-61)培养在EP-48791所述含2mM谷氨酰胺并补加了10%FCS的Iscoves’s DMEM培养基中。可选的是,在如实验1所述进行GS标记选择之前,可用表1所示含2mM谷氨酰胺的G-MEM培养基。使细胞脱壁,沉淀,然后在无血清培养基中重悬两次,最后配成每毫升5.3×106个细胞的密度。每批750μl,总共4×106个细胞接受电穿孔。如《分子生物学方法》,JA Nickoloff编,Humana出版社,1995,Vol.48/Chap.8:“动物细胞电穿孔和电融合方法”所述进行电穿孔。将p12.4mCMV-GFP载体DNA(SEQ ID NO:4)线性化。将50μl(20μg)DNA加入电穿孔小杯内的750μl细胞中,进行300V/750μFD,约12-14毫秒的电穿孔。然后,将800μl细胞转移到T75锥形瓶中的25ml改进型Glasgow-MEM(GMEM,Gibco)培养基(含10%胎血清,但不含谷氨酰胺,详见表1)中进行GS选择。将12.9ml分入第二T75锥形瓶,37℃和10%CO2中培养过夜。
次日,加入补充了10%FBS+33.3μM MSX的GS选择GMEM培养基。这样,MSX的最终浓度约为25μM。继续培养26天后,计点每瓶中的菌落数亦即转染子数。用标准倒置显微镜对每一培养瓶进行显微镜检,阳性克隆发出亮绿的光,因而很容易计点。
SEQ ID NO:4所示的mCMV构建物产生的菌落数比SEQ ID NO:3所示hCMV构建物转染的细胞多20倍。这两种载体构建物的区别仅在于驱动GFP表达的CMV启动子不同,载体的其余部分是一样的(包括GS标记;p12.4的cDNA GS-标记盒)。如果在转染后立即将细胞稀释并加入96格培养板,mCMV细胞形成的菌落(>400个)仍比hCMV转染的细胞(约45个)多。
表1:GS选择培养基
A.储备液
1.双蒸水高压灭菌,每份400ml
2.10×Glasgow MEM(GMEM)培养基,不含谷氨酰胺(GIBCO:042-2541,在UK)。4℃保存。
3.7.5%碳酸氢钠(GIBCO:043-05080,在UK;670-5080,在US)。4℃保存。
4.100×非必需氨基酸(NEAA)(GIBCO:043-01140,在UK;320-1140,在US)。4℃保存。
5.100×谷氨酸+天冬酰胺(G+A):加600mg谷氨酸和600mg天冬酰胺(Sigma)。用蒸馏水配制成100ml,经2μm滤膜(Nalgene)过滤除菌。4℃保存。
6.100mM丙酮酸钠(GIBCO:043-01360,在UK;320-1360,在US)
7.50×核苷:35mg腺苷
35mg鸟苷
35mg胞苷
35mg尿苷
12mg胸苷
都购自Sigma。用水配制成100ml溶液,过滤除菌,分成每份10ml于-20℃保存。
8.经透析FCS(GIBCO:014-06300)。在56℃热灭活30分钟,-20℃保存。采用GS选择时,必需使用经透析FCS。
9.每毫升5000单位的青霉素-链霉素(P/S:GIBCO:043-05070,在UK;600-5070,在US)。
10.100mM L.MSX(Sigma):配成18mg/ml的PBS溶液。过滤除菌,-20℃保存。
B.培养基的制备
以无菌操作按以下顺序依次加入以下物质,配制成GMEM-S培养基。
1.水 400ml
2.10×GMEM 50ml
3.碳酸氢钠 18.1ml
4.NEAA 5ml
5.G+A 5ml
6.丙酮酸钠 5ml
7.核苷 10ml
8.经透析FCS 50ml
9.青霉素-链霉素 5ml
GMEM-S培养基含有非必需氨基酸,丙氨酸,天冬氨酸,甘氨酸,脯氨酸和丝氨酸(100μM),谷氨酸和天冬酰胺(500μM),腺苷,鸟苷,胞苷和尿苷(30μM),以及胸苷(10μM)。
序列表
<110>英国龙沙生物医药股份有限公司
<120>在CHO细胞内表达重组蛋白的方法
<130>049369
<150>GB0216648.6
<151>2002-07-19
<160>4
<170>PatentIn version 3.1
<210>1
<211>6679
<212>DNA
<213>仓鼠(Hamster sp.)
<220>
<221>misc_feature
<223>Seq.ID.No.4:环形质粒GS载体p12.4短mCMV-GFP/克隆3
<400>1
gaattcattg atcataatca gccataccac atttgtagag gttttacttg ctttaaaaaa 60
cctcccacac ctccccctga acctgaaaca taaaatgaat gcaattgttg ttgttaactt 120
gtttattgca gcttataatg gttacaaata aagcaatagc atcacaaatt tcacaaataa 180
agcatttttt tcactgcatt ctagttgtgg tttgtccaaa ctcatcaatg tatcttatca 240
tgtctggcgg ccgcgacctg caggcgcaga actggtaggt atggaagatc cctcgagatc 300
cattgtgctg gcggtaggcg agcagcgcct gcctgaagct gcgggcattc ccagtcagaa 360
atgagcgcca gtcgtcgtcg gctctcggca ccgaagtgct atgattctcc gccagcatgg 420
cttcggccag tgcgtcgagc agcgcccgct tgttcctgaa gtgccagtaa agcgccggct 480
gctgaacccc caaccgttcc gccagtttgc gtgtcgtcag accgtctacg ccgacctcgt 540
tcaacaggtc cagggcggca cggatcactg tattcggctg caactttgtc atgcttgaca 600
ctttatcact gataaacata atatgtccac caacttatca gtgataaaga atccgcgcca 660
gcacaatgga tctcgaggtc gagggatctc tagaggatcc atattcgcgg gcatcaccgg 720
cgccacaggt gcggttgctg gcgcctatat cgccgacatc accgatgggg aagatcgggc 780
tcgccacttc gggctcatga gcgcttgttt cggcgtgggt atggtggcag gccccgtggc 840
cgggggactg ttgggcgcca tctccttgca tgcaccattc cttgcggcgg cggtgctcaa 900
cggcctcaac ctactactgg gctgcttcct aatgcaggag tcgcataagg gagagcgtcg 960
acctcgggcc gcgttgctgg cgtttttcca taggctccgc ccccctgacg agcatcacaa 1020
aaatcgacgc tcaagtcaga ggtggcgaaa cccgacagga ctataaagat accaggcgtt 1080
tccccctgga agctccctcg tgcgctctcc tgttccgacc ctgccgctta ccggatacct 1140
gtccgccttt ctcccttcgg gaagcgtggc gctttctcat agctcacgct gtaggtatct 1200
cagttcggtg taggtcgttc gctccaagct gggctgtgtg cacgaacccc ccgttcagcc 1260
cgaccgctgc gccttatccg gtaactatcg tcttgagtcc aacccggtaa gacacgactt 1320
atcgccactg gcagcagcca ctggtaacag gattagcaga gcgaggtatg taggcggtgc 1380
tacagagttc ttgaagtggt ggcctaacta cggctacact agaagaacag tatttggtat 1440
ctgcgctctg ctgaagccag ttaccttcgg aaaaagagtt ggtagctctt gatccggcaa 1500
acaaaccacc gctggtagcg gtggtttttt tgtttgcaag cagcagatta cgcgcagaaa 1560
aaaaggatct caagaagatc ctttgatctt ttctacgggg tctgacgctc agtggaacga 1620
aaactcacgt taagggattt tggtcatgag attatcaaaa aggatcttca cctagatcct 1680
tttaaattaa aaatgaagtt ttaaatcaat ctaaagtata tatgagtaaa cttggtctga 1740
cagttaccaa tgcttaatca gtgaggcacc tatctcagcg atctgtctat ttcgttcatc 1800
catagttgcc tgactccccg tcgtgtagat aactacgata cgggagggct taccatctgg 1860
ccccagtgct gcaatgatac cgcgagaccc acgctcaccg gctccagatt tatcagcaat 1920
aaaccagcca gccggaaggg ccgagcgcag aagtggtcct gcaactttat ccgcctccat 1980
ccagtctatt aattgttgcc gggaagctag agtaagtagt tcgccagtta atagtttgcg 2040
caacgttgtt gccattgcta caggcatcgt ggtgtcacgc tcgtcgtttg gtatggcttc 2100
attcagctcc ggttcccaac gatcaaggcg agttacatga tcccccatgt tgtgcaaaaa 2160
agcggttagc tccttcggtc ctccgatcgt tgtcagaagt aagttggccg cagtgttatc 2220
actcatggtt atggcagcac tgcataattc tcttactgtc atgccatccg taagatgctt 2280
ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgtatgc ggcgaccgag 2340
ttgctcttgc ccggcgtcaa tacgggataa taccgcgcca catagcagaa ctttaaaagt 2400
gctcatcatt ggaaaacgtt cttcggggcg aaaactctca aggatcttac cgctgttgag 2460
atccagttcg atgtaaccca ctcgtgcacc caactgatct tcagcatctt ttactttcac 2520
cagcgtttct gggtgagcaa aaacaggaag gcaaaatgcc gcaaaaaagg gaataagggc 2580
gacacggaaa tgttgaatac tcatactctt cctttttcaa tattattgaa gcatttatca 2640
gggttattgt ctcatgagcg gatacatatt tgaatgtatt tagaaaaata aacaaatagg 2700
ggttccgcgc acatttcccc gaaaagtgcc acctgacgtc taagaaacca ttattatcat 2760
gacattaacc tataaaaata ggcgtatcac gaggccctga tggctctttg cggcacccat 2820
cgttcgtaat gttccgtggc accgaggaca accctcaaga gaaaatgtaa tcacactggc 2880
tcaccttcgg gtgggccttt ctgcgtttat aaggagacac tttatgttta agaaggttgg 2940
taaattcctt gcggctttgg cagccaagct agatccggct gtggaatgtg tgtcagttag 3000
ggtgtggaaa gtccccaggc tccccagcag gcagaagtat gcaaagcatg catctcaatt 3060
agtcagcaac caggtgtgga aagtccccag gctccccagc aggcagaagt atgcaaagca 3120
tgcatctcaa ttagtcagca accatagtcc cgcccctaac tccgcccatc ccgcccctaa 3180
ctccgcccag ttccgcccat tctccgcccc atggctgact aatttttttt atttatgcag 3240
aggccgaggc cgcctcggcc tctgagctat tccagaagta gtgaggaggc ttttttggag 3300
gcctaggctt ttgcaaaaag ctagcttggg gccaccgctc agagcacctt ccaccatggc 3360
cacctcagca agttcccact tgaacaaaaa catcaagcaa atgtacttgt gcctgcccca 3420
gggtgagaaa gtccaagcca tgtatatctg ggttgatggt actggagaag gactgcgctg 3480
caaaacccgc accctggact gtgagcccaa gtgtgtagaa gagttacctg agtggaattt 3540
tgatggctct agtacctttc agtctgaggg ctccaacagt gacatgtatc tcagccctgt 3600
tgccatgttt cgggacccct tccgcagaga tcccaacaag ctggtgttct gtgaagtttt 3660
caagtacaac cggaagcctg cagagaccaa tttaaggcac tcgtgtaaac ggataatgga 3720
catggtgagc aaccagcacc cctggtttgg aatggaacag gagtatactc tgatgggaac 3780
agatgggcac ccttttggtt ggccttccaa tggctttcct gggccccaag gtccgtatta 3840
ctgtggtgtg ggcgcagaca aagcctatgg cagggatatc gtggaggctc actaccgcgc 3900
ctgcttgtat gctggggtca agattacagg aacaaatgct gaggtcatgc ctgcccagtg 3960
ggaactccaa ataggaccct gtgaaggaat ccgcatggga gatcatctct gggtggcccg 4020
tttcatcttg catcgagtat gtgaagactt tggggtaata gcaacctttg accccaagcc 4080
cattcctggg aactggaatg gtgcaggctg ccataccaac tttagcacca aggccatgcg 4140
ggaggagaat ggtctgaagc acatcgagga ggccatcgag aaactaagca agcggcaccg 4200
gtaccacatt cgagcctacg atcccaaggg gggcctggac aatgcccgtg gtctgactgg 4260
gttccacgaa acgtccaaca tcaacgactt ttctgctggt gtcgccaatc gcagtgccag 4320
catccgcatt ccccggactg tcggccagga gaagaaaggt tactttgaag accgcggccc 4380
ctctgccaat tgtgacccct ttgcagtgac agaagccatc gtccgcacat gccttctcaa 4440
tgagactggc gacgagccct tccaatacaa aaactaatta gactttgagt gatcttgagc 4500
ctttcctagt tcatcccacc ccgccccaga gagatctttg tgaaggaacc ttacttctgt 4560
ggtgtgacat aattggacaa actacctaca gagatttaaa gctctaaggt aaatataaaa 4620
tttttaagtg tataatgtgt taaactactg attctaattg tttgtgtatt ttagattcca 4680
acctatggaa ctgatgaatg ggagcagtgg tggaatgcct ttaatgagga aaacctgttt 4740
tgctcagaag aaatgccatc tagtgatgat gaggctactg ctgactctca acattctact 4800
cctccaaaaa agaagagaaa ggtagaagac cccaaggact ttccttcaga attgctaagt 4860
tttttgagtc atgctgtgtt tagtaataga actcttgctt gctttgctat ttacaccaca 4920
aaggaaaaag ctgcactgct atacaagaaa attatggaaa aatattctgt aacctttata 4980
agtaggcata acagttataa tcataacata ctgttttttc ttactccaca caggcataga 5040
gtgtctgcta ttaataacta tgctcaaaaa ttgtgtacct ttagcttttt aatttgtaaa 5100
ggggttaata aggaatattt gatgtatagt gccttgacta gagatcataa tcagccatac 5160
cacatttgta gaggttttac ttgctttaaa aaacctccca cacctccccc tgaacctgaa 5220
acataaaatg aatgcaattg ttgttgttaa cttgtttatt gcagcttata atggttacaa 5280
ataaagcaat agcatcacaa atttcacaaa taaagcattt ttttcactgc attctagttg 5340
tggtttgtcc aaactcatca atgtatctta tcatgtctgg atctctagct tcgtgtcaag 5400
gacggtgagg cgcgcctact gagtcattag ggactttcca atgggttttg cccagtacat 5460
aaggtcaata ggggtgaatc aacaggaaag tcccattgga gccaagtaca ctgagtcaat 5520
agggactttc cattgggttt tgcccagtac aaaaggtcaa tagggggtga gtcaatgggt 5580
ttttcccatt attggcacgt acataaggt caataggggtg agtcattggg tttttccagc 5640
caatttaatt aaaacgccat gtactttccc accattgacg tcaatgggct attgaaacta 5700
atgcaacgtg acctttaaac ggtactttcc catagctgat taatgggaaa gtaccgttct 5760
cgagccaata cacgtcaatg ggaagtgaaa gggcagccaa aacgtaacac cgccccggtt 5820
ttcccctgga aattccatat tggcacgcat tctattggct gagctgcgtt ctacgtgggt 5880
ataagaggcg cgaccagcgt cggtaccgtc gcagtcttcg gtctgaccac cgtagaacgc 5940
agaagcttgc cgccaccatg gtgagcaagc agatcctgaa gaacaccggc ctgcaggaga 6000
tcatgagctt caaggtgaac ctggagggcg tggtgaacaa ccacgtgttc accatggagg 6060
gctgcggcaa gggcaacatc ctgttcggca accagctggt gcagatccgc gtgaccaagg 6120
gcgcccccct gcccttcgcc ttcgacatcc tgagccccgc cttccagtac ggcaaccgca 6180
ccttcaccaa gtaccccgag gacatcagcg acttcttcat ccagagcttc cccgccggct 6240
tcgtgtacga gcgcaccctg cgctacgagg acggcggcct ggtggagatc cgcagcgaca 6300
tcaacctgat cgaggagatg ttcgtgtacc gcgtggagta caagggccgc aacttcccca 6360
acgacggccc cgtgatgaag aagaccatca ccggcctgca gcccagcttc gaggtggtgt 6420
acatgaacga cggcgtgctg gtgggccagg tgatcctggt gtaccgcctg aacagcggca 6480
agttctacag ctgccacatg cgcaccctga tgaagagcaa gggcgtggtg aaggacttcc 6540
ccgagtacca cttcatccag caccgcctgg agaagaccta cgtggaggac ggcggcttcg 6600
tggagcagca cgagaccgcc atcgcccagc tgaccagcct gggcaagccc ctgggcagcc 6660
tgcacgagtg ggtgtaata 6679
<210>2
<211>8251
<212>DNA
<213>仓鼠(Hamster sp.)
<220>
<221>misc_feature
<223>Seq.ID.No.3:环形质粒GS载体p12.4 hCMVp-6FP/克隆13
<400>2
gaattcattg atcataatca gccataccac atttgtagag gttttacttg ctttaaaaaa 60
cctcccacac ctccccctga acctgaaaca taaaatgaat gcaattgttg ttgttaactt 120
gtttattgca gcttataatg gttacaaata aagcaatagc atcacaaatt tcacaaataa 180
agcatttttt tcactgcatt ctagttgtgg tttgtccaaa ctcatcaatg tatcttatca 240
tgtctggcgg ccgcgacctg caggcgcaga actggtaggt atggaagatc cctcgagatc 300
cattgtgctg gcggtaggcg agcagcgcct gcctgaagct gcgggcattc ccagtcagaa 360
atgagcgcca gtcgtcgtcg gctctcggca ccgaagtgct atgattctcc gccagcatgg 420
cttcggccag tgcgtcgagc agcgcccgct tgttcctgaa gtgccagtaa agcgccggct 480
gctgaacccc caaccgttcc gccagtttgc gtgtcgtcag accgtctacg ccgacctcgt 540
tcaacaggtc cagggcggca cggatcactg tattcggctg caactttgtc atgcttgaca 600
ctttatcact gataaacata atatgtccac caacttatca gtgataaaga atccgcgcca 660
gcacaatgga tctcgaggtc gagggatctc tagaggatcc atattcgcgg gcatcaccgg 720
cgccacaggt gcggttgctg gcgcctatat cgccgacatc accgatgggg aagatcgggc 780
tcgccacttc gggctcatga gcgcttgttt cggcgtgggt atggtggcag gccccgtggc 840
cgggggactg ttgggcgcca tctccttgca tgcaccattc cttgcggcgg cggtgctcaa 900
cggcctcaac ctactactgg gctgcttcct aatgcaggag tcgcataagg gagagcgtcg 960
acctcgggcc gcgttgctgg cgtttttcca taggctccgc ccccctgacg agcatcacaa 1020
aaatcgacgc tcaagtcaga ggtggcgaaa cccgacagga ctataaagat accaggcgtt 1080
tccccctgga agctccctcg tgcgctctcc tgttccgacc ctgccgctta ccggatacct 1140
gtccgccttt ctcccttcgg gaagcgtggc gctttctcat agctcacgct gtaggtatct 1200
cagttcggtg taggtcgttc gctccaagct gggctgtgtg cacgaacccc ccgttcagcc 1260
cgaccgctgc gccttatccg gtaactatcg tcttgagtcc aacccggtaa gacacgactt 1320
atcgccactg gcagcagcca ctggtaacag gattagcaga gcgaggtatg taggcggtgc 1380
tacagagttc ttgaagtggt ggcctaacta cggctacact agaagaacag tatttggtat 1440
ctgcgctctg ctgaagccag ttaccttcgg aaaaagagtt ggtagctctt gatccggcaa 1500
acaaaccacc gctggtagcg gtggtttttt tgtttgcaag cagcagatta cgcgcagaaa 1560
aaaaggatct caagaagatc ctttgatctt ttctacgggg tctgacgctc agtggaacga 1620
aaactcacgt taagggattt tggtcatgag attatcaaaa aggatcttca cctagatcct 1680
tttaaattaa aaatgaagtt ttaaatcaat ctaaagtata tatgagtaaa cttggtctga 1740
cagttaccaa tgcttaatca gtgaggcacc tatctcagcg atctgtctat ttcgttcatc 1800
catagttgcc tgactccccg tcgtgtagat aactacgata cgggagggct taccatctgg 1860
ccccagtgct gcaatgatac cgcgagaccc acgctcaccg gctccagatt tatcagcaat 1920
aaaccagcca gccggaaggg ccgagcgcag aagtggtcct gcaactttat ccgcctccat 1980
ccagtctatt aattgttgcc gggaagctag agtaagtagt tcgccagtta atagtttgcg 2040
caacgttgtt gccattgcta caggcatcgt ggtgtcacgc tcgtcgtttg gtatggcttc 2100
attcagctcc ggttcccaac gatcaaggcg agttacatga tcccccatgt tgtgcaaaaa 2160
agcggttagc tccttcggtc ctccgatcgt tgtcagaagt aagttggccg cagtgttatc 2220
actcatggtt atggcagcac tgcataattc tcttactgtc atgccatccg taagatgctt 2280
ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgtatgc ggcgaccgag 2340
ttgctcttgc ccggcgtcaa tacgggataa taccgcgcca catagcagaa ctttaaaagt 2400
gctcatcatt ggaaaacgtt cttcggggcg aaaactctca aggatcttac cgctgttgag 2460
atccagttcg atgtaaccca ctcgtgcacc caactgatct tcagcatctt ttactttcac 2520
cagcgtttct gggtgagcaa aaacaggaag gcaaaatgcc gcaaaaaagg gaataagggc 2580
gacacggaaa tgttgaatac tcatactctt cctttttcaa tattattgaa gcatttatca 2640
gggttattgt ctcatgagcg gatacatatt tgaatgtatt tagaaaaata aacaaatagg 2700
ggttccgcgc acatttcccc gaaaagtgcc acctgacgtc taagaaacca ttattatcat 2760
gacattaacc tataaaaata ggcgtatcac gaggccctga tggctctttg cggcacccat 2820
cgttcgtaat gttccgtggc accgaggaca accctcaaga gaaaatgtaa tcacactggc 2880
tcaccttcgg gtgggccttt ctgcgtttat aaggagacac tttatgttta agaaggttgg 2940
taaattcctt gcggctttgg cagccaagct agatccggct gtggaatgtg tgtcagttag 3000
ggtgtggaaa gtccccaggc tccccagcag gcagaagtat gcaaagcatg catctcaatt 3060
agtcagcaac caggtgtgga aagtccccag gctccccagc aggcagaagt atgcaaagca 3120
tgcatctcaa ttagtcagca accatagtcc cgcccctaac tccgcccatc ccgcccctaa 3180
ctccgcccag ttccgcccat tctccgcccc atggctgact aatttttttt atttatgcag 3240
aggccgaggc cgcctcggcc tctgagctat tccagaagta gtgaggaggc ttttttggag 3300
gcctaggctt ttgcaaaaag ctagcttggg gccaccgctc agagcacctt ccaccatggc 3360
cacctcagca agttcccact tgaacaaaaa catcaagcaa atgtacttgt gcctgcccca 3420
gggtgagaaa gtccaagcca tgtatatctg ggttgatggt actggagaag gactgcgctg 3480
caaaacccgc accctggact gtgagcccaa gtgtgtagaa gagttacctg agtggaattt 3540
tgatggctct agtacctttc agtctgaggg ctccaacagt gacatgtatc tcagccctgt 3600
tgccatgttt cgggacccct tccgcagaga tcccaacaag ctggtgttct gtgaagtttt 3660
caagtacaac cggaagcctg cagagaccaa tttaaggcac tcgtgtaaac ggataatgga 3720
catggtgagc aaccagcacc cctggtttgg aatggaacag gagtatactc tgatgggaac 3780
agatgggcac ccttttggtt ggccttccaa tggctttcct gggccccaag gtccgtatta 3840
ctgtggtgtg ggcgcagaca aagcctatgg cagggatatc gtggaggctc actaccgcgc 3900
ctgcttgtat gctggggtca agattacagg aacaaatgct gaggtcatgc ctgcccagtg 3960
ggaactccaa ataggaccct gtgaaggaat ccgcatggga gatcatctct gggtggcccg 4020
tttcatcttg catcgagtat gtgaagactt tggggtaata gcaacctttg accccaagcc 4080
cattcctggg aactggaatg gtgcaggctg ccataccaac tttagcacca aggccatgcg 4140
ggaggagaat ggtctgaagc acatcgagga ggccatcgag aaactaagca agcggcaccg 4200
gtaccacatt cgagcctacg atcccaaggg gggcctggac aatgcccgtg gtctgactgg 4260
gttccacgaa acgtccaaca tcaacgactt ttctgctggt gtcgccaatc gcagtgccag 4320
catccgcatt ccccggactg tcggccagga gaagaaaggt tactttgaag accgcggccc 4380
ctctgccaat tgtgacccct ttgcagtgac agaagccatc gtccgcacat gccttctcaa 4440
tgagactggc gacgagccct tccaatacaa aaactaatta gactttgagt gatcttgagc 4500
ctttcctagt tcatcccacc ccgccccaga gagatctttg tgaaggaacc ttacttctgt 4560
ggtgtgacat aattggacaa actacctaca gagatttaaa gctctaaggt aaatataaaa 4620
tttttaagtg tataatgtgt taaactactg attctaattg tttgtgtatt ttagattcca 4680
acctatggaa ctgatgaatg ggagcagtgg tggaatgcct ttaatgagga aaacctgttt 4740
tgctcagaag aaatgccatc tagtgatgat gaggctactg ctgactctca acattctact 4800
cctccaaaaa agaagagaaa ggtagaagac cccaaggact ttccttcaga attgctaagt 4860
tttttgagtc atgctgtgtt tagtaataga actcttgctt gctttgctat ttacaccaca 4920
aaggaaaaag ctgcactgct atacaagaaa attatggaaa aatattctgt aacctttata 4980
agtaggcata acagttataa tcataacata ctgttttttc ttactccaca caggcataga 5040
gtgtctgcta ttaataacta tgctcaaaaa ttgtgtacct ttagcttttt aatttgtaaa 5100
ggggttaata aggaatattt gatgtatagt gccttgacta gagatcataa tcagccatac 5160
cacatttgta gaggttttac ttgctttaaa aaacctccca cacctccccc tgaacctgaa 5220
acataaaatg aatgcaattg ttgttgttaa cttgtttatt gcagcttata atggttacaa 5280
ataaagcaat agcatcacaa atttcacaaa taaagcattt ttttcactgc attctagttg 5340
tggtttgtcc aaactcatca atgtatctta tcatgtctgg atctagcttc gtgtcaagga 5400
cggtgactgc agtgaataat aaaatgtgtg tttgtccgaa atacgcgttt tgagatttct 5460
gtcgccgact aaattcatgt cgcgcgatag tggtgtttat cgccgataga gatggcgata 5520
ttggaaaaat cgatatttga aaatatggca tattgaaaat gtcgccgatg tgagtttctg 5580
tgtaactgat atcgccattt ttccaaaagt gatttttggg catacgcgat atctggcgat 5640
agcgcttata tcgtttacgg gggatggcga tagacgactt tggtgacttg ggcgattctg 5700
tgtgtcgcaa atatcgcagt ttcgatatag gtgacagacg atatgaggct atatcgccga 5760
tagaggcgac atcaagctgg cacatggcca atgcatatcg atctatacat tgaatcaata 5820
ttggccatta gccatattat tcattggtta tatagcataa atcaatattg gctattggcc 5880
attgcatacg ttgtatccat atcataatat gtacatttat attggctcat gtccaacatt 5940
accgccatgt tgacattgat tattgactag ttattaatag taatcaatta cggggtcatt 6000
agttcatagc ccatatatgg agttccgcgt tacataactt acggtaaatg gcccgcctgg 6060
ctgaccgccc aacgaccccc gcccattgac gtcaataatg acgtatgttc ccatagtaac 6120
gccaataggg actttccatt gacgtcaatg ggtggagtat ttacggtaaa ctgcccactt 6180
ggcagtacat caagtgtatc atatgccaag tacgccccct attgacgtca atgacggtaa 6240
atggcccgcc tggcattatg cccagtacat gaccttatgg gactttccta cttggcagta 6300
catctacgta ttagtcatcg ctattaccat ggtgatgcgg ttttggcagt acatcaatgg 6360
gcgtggatag cggtttgact cacggggatt tccaagtctc caccccattg acgtcaatgg 6420
gagtttgttt tggcaccaaa atcaacggga ctttccaaaa tgtcgtaaca actccgcccc 6480
attgacgcaa atgggcggta ggcgtgtacg gtgggaggtc tatataagca gagctcgttt 6540
agtgaaccgt cagatcgcct ggagacgcca tccacgctgt tttgacctcc atagaagaca 6600
ccgggaccga tccagcctcc gcggccggga acggtgcatt ggaacgcgga ttccccgtgc 6660
caagagtgac gtaagtaccg cctatagagt ctataggccc acccccttgg cttcttatgc 6720
atgctatact gtttttggct tggggtctat acacccccgc ttcctcatgt tataggtgat 6780
ggtatagctt agcctatagg tgtgggttat tgaccattat tgaccactcc cctattggtg 6840
acgatacttt ccattactaa tccataacat ggctctttgc cacaactctc tttattggct 6900
atatgccaat acactgtcct tcagagactg acacggactc tgtattttta caggatgggg 6960
tctcatttat tatttacaaa ttcacatata caacaccacc gtccccagtg cccgcagttt 7020
ttattaaaca taacgtggga tctccacgcg aatctcgggt acgtgttccg gacatgggct 7080
cttctccggt agcggcggag cttctacatc cgagccctgc tcccatgcct ccagcgactc 7140
atggtcgctc ggcagctcct tgctcctaac agtggaggcc agacttaggc acagcacgat 7200
gcccaccacc accagtgtgc cgcacaaggc cgtggcggta gggtatgtgt ctgaaaatga 7260
gctcggggag cgggcttgca ccgctgacgc atttggaaga cttaaggcag cggcagaaga 7320
agatgcaggc agctgagttg ttgtgttctg ataagagtca gaggtaactc ccgttgcggt 7380
gctgttaacg gtggagggca gtgtagtctg agcagtactc gttgctgccg cgcgcgccac 7440
cagacataat agctgacaga ctaacagact gttcctttcc atgggtcttt tctgcagtca 7500
ccgtccttga cacgaagctt gccgccacca tggtgagcaa gcagatcctg aagaacaccg 7560
gcctgcagga gatcatgagc ttcaaggtga acctggaggg cgtggtgaac aaccacgtgt 7620
tcaccatgga gggctgcggc aagggcaaca tcctgttcgg caaccagctg gtgcagatcc 7680
gcgtgaccaa gggcgccccc ctgcccttcg ccttcgacat cctgagcccc gccttccagt 7740
acggcaaccg caccttcacc aagtaccccg aggacatcag cgacttcttc atccagagct 7800
tccccgccgg cttcgtgtac gagcgcaccc tgcgctacga ggacggcggc ctggtggaga 7860
tccgcagcga catcaacctg atcgaggaga tgttcgtgta ccgcgtggag tacaagggcc 7920
gcaacttccc caacgacggc cccgtgatga agaagaccat caccggcctg cagcccagct 7980
tcgaggtggt gtacatgaac gacggcgtgc tggtgggcca ggtgatcctg gtgtaccgcc 8040
tgaacagcgg caagttctac agctgccaca tgcgcaccct gatgaagagc aagggcgtgg 8100
tgaaggactt ccccgagtac cacttcatcc agcaccgcct ggagaagacc tacgtggagg 8160
acggcggctt cgtggagcag cacgagaccg ccatcgccca gctgaccagc ctgggcaagc 8220
ccctgggcag cctgcacgag tgggtgtaat a 8251
<210>3
<211>10369
<212>DNA
<213>仓鼠(Hamster sp.)
<220>
<221>misc_feature
<223>Seq.ID.No.2:环形质粒GS-小基因载体p14.4 Delta调节子(mod-)
hCMVp-GFP/克隆6
<400>3
gaattcattg atcataatca gccataccac atttgtagag gttttacttg ctttaaaaaa 60
cctcccacac ctccccctga acctgaaaca taaaatgaat gcaattgttg ttgttaactt 120
gtttattgca gcttataatg gttacaaata aagcaatagc atcacaaatt tcacaaataa 180
agcatttttt tcactgcatt ctagttgtgg tttgtccaaa ctcatcaatg tatcttatca 240
tgtctggcgg ccgcgacctg caggcgcaga actggtaggt atggaagatc cctcgagatc 300
cattgtgctg gcggtaggcg agcagcgcct gcctgaagct gcgggcattc ccagtcagaa 360
atgagcgcca gtcgtcgtcg gctctcggca ccgaagtgct atgattctcc gccagcatgg 420
cttcggccag tgcgtcgagc agcgcccgct tgttcctgaa gtgccagtaa agcgccggct 480
gctgaacccc caaccgttcc gccagtttgc gtgtcgtcag accgtctacg ccgacctcgt 540
tcaacaggtc cagggcggca cggatcactg tattcggctg caactttgtc atgcttgaca 600
ctttatcact gataaacata atatgtccac caacttatca gtgataaaga atccgcgcca 660
gcacaatgga tctcgaggtc gagggatctc tagaggatcc atattcgcgg gcatcaccgg 720
cgccacaggt gcggttgctg gcgcctatat cgccgacatc accgatgggg aagatcgggc 780
tcgccacttc gggctcatga gcgcttgttt cggcgtgggt atggtggcag gccccgtggc 840
cgggggactg ttgggcgcca tctccttgca tgcaccattc cttgcggcgg cggtgctcaa 900
cggcctcaac ctactactgg gctgcttcct aatgcaggag tcgcataagg gagagcgtcg 960
acctcgggcc gcgttgctgg cgtttttcca taggctccgc ccccctgacg agcatcacaa 1020
aaatcgacgc tcaagtcaga ggtggcgaaa cccgacagga ctataaagat accaggcgtt 1080
tccccctgga agctccctcg tgcgctctcc tgttccgacc ctgccgctta ccggatacct 1140
gtccgccttt ctcccttcgg gaagcgtggc gctttctcat agctcacgct gtaggtatct 1200
cagttcggtg taggtcgttc gctccaagct gggctgtgtg cacgaacccc ccgttcagcc 1260
cgaccgctgc gccttatccg gtaactatcg tcttgagtcc aacccggtaa gacacgactt 1320
atcgccactg gcagcagcca ctggtaacag gattagcaga gcgaggtatg taggcggtgc 1380
tacagagttc ttgaagtggt ggcctaacta cggctacact agaagaacag tatttggtat 1440
ctgcgctctg ctgaagccag ttaccttcgg aaaaagagtt ggtagctctt gatccggcaa 1500
acaaaccacc gctggtagcg gtggtttttt tgtttgcaag cagcagatta cgcgcagaaa 1560
aaaaggatct caagaagatc ctttgatctt ttctacgggg tctgacgctc agtggaacga 1620
aaactcacgt taagggattt tggtcatgag attatcaaaa aggatcttca cctagatcct 1680
tttaaattaa aaatgaagtt ttaaatcaat ctaaagtata tatgagtaaa cttggtctga 1740
cagttaccaa tgcttaatca gtgaggcacc tatctcagcg atctgtctat ttcgttcatc 1800
catagttgcc tgactccccg tcgtgtagat aactacgata cgggagggct taccatctgg 1860
ccccagtgct gcaatgatac cgcgagaccc acgctcaccg gctccagatt tatcagcaat 1920
aaaccagcca gccggaaggg ccgagcgcag aagtggtcct gcaactttat ccgcctccat 1980
ccagtctatt aattgttgcc gggaagctag agtaagtagt tcgccagtta atagtttgcg 2040
caacgttgtt gccattgcta caggcatcgt ggtgtcacgc tcgtcgtttg gtatggcttc 2100
attcagctcc ggttcccaac gatcaaggcg agttacatga tcccccatgt tgtgcaaaaa 2160
agcggttagc tccttcggtc ctccgatcgt tgtcagaagt aagttggccg cagtgttatc 2220
actcatggtt atggcagcac tgcataattc tcttactgtc atgccatccg taagatgctt 2280
ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgtatgc ggcgaccgag 2340
ttgctcttgc ccggcgtcaa tacgggataa taccgcgcca catagcagaa ctttaaaagt 2400
gctcatcatt ggaaaacgtt cttcggggcg aaaactctca aggatcttac cgctgttgag 2460
atccagttcg atgtaaccca ctcgtgcacc caactgatct tcagcatctt ttactttcac 2520
cagcgtttct gggtgagcaa aaacaggaag gcaaaatgcc gcaaaaaagg gaataagggc 2580
gacacggaaa tgttgaatac tcatactctt cctttttcaa tattattgaa gcatttatca 2640
gggttattgt ctcatgagcg gatacatatt tgaatgtatt tagaaaaata aacaaatagg 2700
ggttccgcgc acatttcccc gaaaagtgcc acctgacgtc taagaaacca ttattatcat 2760
gacattaacc tataaaaata ggcgtatcac gaggccctga tggctctttg cggcacccat 2820
cgttcgtaat gttccgtggc accgaggaca accctcaaga gaaaatgtaa tcacactggc 2880
tcaccttcgg gtgggccttt ctgcgtttat aaggagacac tttatgttta agaaggttgg 2940
taaattcctt gcggctttgg cagccaagct agatccagct ttttgcaaaa gcctaggcct 3000
ccaaaaaagc ctcctcacta cttctggaat agctcagagg ccgaggcggc ctcggcctct 3060
gcataaataa aaaaaattag tcagccatgg ggcggagaat gggcggaact gggcggagtt 3120
aggggcggga tgggcggagt taggggcggg actatggttg ctgactaatt gagatgcatg 3180
ctttgcatac ttctgcctgc tggggagcct ggggactttc cacacctggt tgctgactaa 3240
ttgagatgca tgctttgcat acttctgcct gctggggagc ctggggactt tccacaccct 3300
aactgacaca cattccacag ggaagctagc ttggaattaa ttccccgccc ccttccaata 3360
caaaaactaa ttagactttg agtgatcttg agcctttcct agtttttgta ttggaagggc 3420
tcgtcgccag tctcattgag aaggcatgtg cggacgatgg cttctgtcac tgcaaagggg 3480
tcacaattgg cagaggggcg gcggtcttca aagtaacctt tcttctcctg ccgagccgag 3540
aatgggagta gagccgactg cttgattccc acaccaatct cctcgccgct ctcacttcgc 3600
ctcgttctcg tggctcgtgg ccctgtccac cccgtccatc atcccgccgg ccaccgctca 3660
gagcaccttc caccatggcc acctcagcaa gttcccactt gaacaaaaac atcaagcaaa 3720
tgtacttgtg cctgccccag ggtgagaaag tccaagccat gtatatctgg gttgatggta 3780
ctggagaagg actgcgctgc aaaacccgca ccctggactg tgagcccaag tgtgtagaag 3840
agttacctga gtggaatttt gatggctcta gtacctttca gtctgagggc tccaacagtg 3900
acatgtatct cagccctgtt gccatgtttc gggacccctt ccgcagagat cccaacaagc 3960
tggtgttctg tgaagttttc aagtacaacc ggaagcctgc agagaccaat ttaaggcact 4020
cgtgtaaacg gataatggac atggtgagca accagcaccc ctggtttgga atggaacagg 4080
agtatactct gatgggaaca gatgggcacc cttttggttg gccttccaat ggctttcctg 4140
ggccccaagg tccgtattac tgtggtgtgg gcgcagacaa agcctatggc agggatatcg 4200
tggaggctca ctaccgcgcc tgcttgtatg ctggggtcaa gattacagga acaaatgctg 4260
aggtcatgcc tgcccagtgg gaactccaaa taggaccctg tgaaggaatc cgcatgggag 4320
atcatctctg ggtggcccgt ttcatcttgc atcgagtatg tgaagacttt ggggtaatag 4380
caacctttga ccccaagccc attcctggga actggaatgg tgcaggctgc cataccaact 4440
ttagcaccaa ggccatgcgg gaggagaatg gtctgaagta agtagctccc tctggaccat 4500
ctttattctc atggggtgga aggcctttgt gttagggttg ggaaaagttg gacttctcac 4560
aaactacatg ccatgctctt cgtgtttgtc ataagcctat cgttttgtac ccgttggaga 4620
agtgacagta ctctaggaat agaattacag ctgtgatatg ggaaagttgt cacgtaggtt 4680
caagcattta aaggtcttta gtaagaacta aatacacata caagcaagtg ggtgacttaa 4740
ttcttactga tgggaagagg ccagtgatgg gggtcttccc atccaaaaga taattggtat 4800
tacatgttga ggactggtct gaagcacttg agacataggt cacaaggcag acacagcctg 4860
catcaagtat ttattggttt cttatggaac tcatgcctgc tcctgccctt gaaggacagg 4920
tttctagtga caaggtcaga ccctcacctt tactgcttcc accaggcaca tcgaggaggc 4980
catcgagaaa ctaagcaagc ggcaccggta ccacattcga gcctacgatc ccaagggggg 5040
gctggacaat gcccgtggtc tgactgggtt ccacgaaacg tccaacatca acgacttttc 5100
tgctggtgtc gccaatcgca gtgccagcat ccgcattccc cggactgtcg gccaggagaa 5160
gaaaggttac tttgaagacc gccgcccctc tgccaattgt gacccctttg cagtgacaga 5220
agccatcgtc cgcacatgcc ttctcaatga gactggcgac gagcccttcc aatacaaaaa 5280
ctaattagac tttgagtgat cttgagcctt tcctagttca tgccaccccg ccccagctgt 5340
ctcattgtaa ctcaaaggat ggaatatcaa cggtcttttt attcctcgtg cccagttaat 5400
ccttgctttt attggtcaga atagaggagt caagttctta atgcctatac accaacctca 5460
tttcttttct atttagcttt ctacgtgggg gtgggagggg tagggagggg taggcgaagg 5520
gaacgtaacc acatgcttca tctcatcagg aatgccatgt ccagtaggca gagctgccac 5580
agagtgggtg tatttgtgga ggaggacttt ttcttcagga cagttaaaag agcaggtcca 5640
ctgcttggat tgacaattcc cctataggta gagagcttgc tagttcttca ggtaaaccaa 5700
ctttctattc caaatggaag ttaggtgagg agtagtggag gagttaatgc cctccatgaa 5760
gacagctcag tgtatcacct gagacagatg ggtagcccta ctgtaaaaga aggaaaagtt 5820
atttctgggt cctccattta taacacaaag cagtagtatt tttatattta aatgtaaaaa 5880
caaaagttat atatatgata tgtggatata tgtgtatttc taattcagaa accatcctag 5940
ttactgggtt tgccaagttt gaagagcttg gttaacaaga aaggatctct tgagtagagg 6000
tgggggtgca gtaccaggaa aggtggttat ctggggctca gcgctttatt actatgtggg 6060
gtttcccctg cccactctgc aggagcagat gctggacagg tagcagggtg ggacaccagt 6120
gcttgccacc acctgtccct gtgcttaggc taagatgcat atgtatccac acagagttag 6180
caggatggag ttggctggtc aacttgaaca ttgttactga taggggtggg tggggtttat 6240
tttttggtgg gactagcatg tcactaaagc aggccttttg atatattaaa ttttttaaag 6300
caaaacaagt tcagctttta atcaactttg tagggtttct aactttacag aattgcctgt 6360
ttgtttcagt gtctccatcc actttgctct tggaggaacg gaggacaggc agacctggag 6420
ttaaaacatt tgtcattttg tgtcatagtg tctactttct cccagcagaa tattcctttc 6480
cttcttagga gtcctatgga gttttgtttt tgtttttttt ctattacgat aaacataccc 6540
cacctccatt ctggcttgcc ctgctgttct ctggttgttt gtgtgctgtc cgcagcaggc 6600
tgcctgtggt tttctcttgc catgacgact tctaattgcc atgtacagta tgttcagtta 6660
gataactcct cattgtaaac agactgtaac tgccagagca gcgcttataa atcaacctaa 6720
catttataag atttcctctt gacttgtttc tttgtggttg ggggaggaag aaaaaaaaaa 6780
gcgtgcagta tttttttgtt ccttcatttc ctatcaaaag aaaggggagt ggttctgttt 6840
tgtttactcg caaaataagc tagcttatct attggctttt cttttttttt ttttttttaa 6900
acgggctttt tcttgtacct ataatttggg gtaaggtgtg agagttttta tagttttttg 6960
agacagggtc ttggtgtata cccttggctg gcctggagct aactatgtag actgggctag 7020
cctttaactt gcagttctgc tttcaattag ggtttataca tttagtcttg gcaattccta 7080
gttccacgtt taatctcttt acatttcaaa gcagtgttat ctgaagagtt caggcgcaga 7140
gtcaattcaa tagagttaca caaaaaccta aaaaacaagt tttaaatacc aagttatgtt 7200
ggcctggcca cttttcacag ctgtccacaa ctcaatgtga caaggctaca aattggatat 7260
actagaattt cctggtgatt tggaacccct gcttcatttc ccggaaccag ggcttttggt 7320
gacagtccta gcttatcaga ttatttaaaa cagttactct tcctgccctt cttcctgaga 7380
cctttgtcca gctgccatga gccatctaca cagtacttgc ttccctgttg aagtcactga 7440
aggcacatca gcccaagaca taaaggcttg tcccggattc actagcctgg tgaacttgtg 7500
gttctctgat gttttgtcct gttttgttgt gatttagtct caaatttccc agcctggttt 7560
gaaaatctgg gctcccagcc ttcaataagg aggactacag atatgtacga ctgagccttg 7620
attccagcct catgtttata cgtctgtgct cagctccctg aaggttccag tttgaaactc 7680
aataatccag gggtcagaaa gtcttgatct tatccccaca gtatggcacc aagcctggct 7740
gagccttctg acttagtctg ccctgttgct atttaagcac ttttcttcac taggctaaaa 7800
ataaaaggag cttcctcctt tgccatggcg ctgtgcatga taggaaaagg tagctatcta 7860
ctagcatatt aactccactg tttttgcttt gtgtgtttgg tttttgagga agggtctcaa 7920
ctgtgtatcc ctggctggcc tggccggatc tagcttcgtg tcaaggacgg tgaggcgcgc 7980
caatattggc tattggccat tgcatacgtt gtatccatat cataatatgt acatttatat 8040
tggctcatgt ccaacattac cgccatgttg acattgatta ttgactagtt attaatagta 8100
atcaattacg gggtcattag ttcatagccc atatatggag ttccgcgtta cataacttac 8160
ggtaaatggc ccgcctggct gaccgcccaa cgacccccgc ccattgacgt caataatgac 8220
gtatgttccc atagtaacgc caatagggac tttccattga cgtcaatggg tggagtattt 8280
acggtaaact gcccacttgg cagtacatca agtgtatcat atgccaagta cgccccctat 8340
tgacgtcaat gacggtaaat ggcccgcctg gcattatgcc cagtacatga ccttatggga 8400
ctttcctact tggcagtaca tctacgtatt agtcatcgct attaccatgg tgatgcggtt 8460
ttggcagtac atcaatgggc gtggatagcg gtttgactca cggggatttc caagtctcca 8520
ccccattgac gtcaatggga gtttgttttg gcaccaaaat caacgggact ttccaaaatg 8580
tcgtaacaac tccgccccat tgacgcaaat gggcggtagg cgtgtacggt gggaggtcta 8640
tataagcaga gctcgtttag tgaaccgtca gatcgcctgg agacgccatc cacgctgttt 8700
tgacctccat agaagacacc gggaccgatc cagcctccgc ggccgggaac ggtgcattgg 8760
aacgcggatt ccccgtgcca agagtgacgt aagtaccgcc tatagagtct ataggcccac 8820
ccccttggct tcttatgcat gctatactgt ttttggcttg gggtctatac acccccgctt 8880
cctcatgtta taggtgatgg tatagcttag cctataggtg tgggttattg accattattg 8940
accactcccc tattggtgac gatactttcc attactaatc cataacatgg ctctttgcca 9000
caactctctt tattggctat atgccaatac actgtccttc agagactgac acggactctg 9060
tatttttaca ggatggggtc tcatttatta tttacaaatt cacatataca acaccaccgt 9120
ccccagtgcc cgcagttttt attaaacata acgtgggatc tccacgcgaa tctcgggtac 9180
gtgttccgga catgggctct tctccggtag cggcggagct tctacatccg agccctgctc 9240
ccatgcctcc agcgactcat ggtcgctcgg cagctccttg ctcctaacag tggaggccag 9300
acttaggcac agcacgatgc ccaccaccac cagtgtgccg cacaaggccg tggcggtagg 9360
gtatgtgtct gaaaatgagc tcggggagcg ggcttgcacc gctgacgcat ttggaagact 9420
taaggcagcg gcagaagaag atgcaggcag ctgagttgtt gtgttctgat aagagtcaga 9480
ggtaactccc gttgcggtgc tgttaacggt ggagggcagt gtagtctgag cagtactcgt 9540
tgctgccgcg cgcgccacca gacataatag ctgacagact aacagactgt tcctttccat 9600
gggtcttttc tgcagtcacc gtccttgaca cgaagcttgc cgccaccatg gtgagcaagc 9660
agatcctgaa gaacaccggc ctgcaggaga tcatgagctt caaggtgaac ctggagggcg 9720
tggtgaacaa ccacgtgttc accatggagg gctgcggcaa gggcaacatc ctgttcggca 9780
accagctggt gcagatccgc gtgaccaagg gcgcccccct gcccttcgcc ttcgacatcc 9840
tgagccccgc cttccagtac ggcaaccgca ccttcaccaa gtaccccgag gacatcagcg 9900
acttcttcat ccagagcttc cccgccggct tcgtgtacga gcgcaccctg cgctacgagg 9960
acggcggcct ggtggagatc cgcagcgaca tcaacctgat cgaggagatg ttcgtgtacc 10020
gcgtggagta caagggccgc aacttcccca acgacggccc cgtgatgaag aagaccatca 10080
ccggcctgca gcccagcttc gaggtggtgt acatgaacga cggcgtgctg gtgggccagg 10140
tgatcctggt gtaccgcctg aacagcggca agttctacag ctgccacatg cgcaccctga 10200
tgaagagcaa gggcgtggtg aaggacttcc ccgagtacca cttcatccag caccgcctgg 10260
agaagaccta cgtggaggac ggcggcttcg tggagcagca cgagaccgcc atcgcccagc 10320
tgaccagcct gggcaagccc ctgggcagcc tgcacgagtg ggtgtaata 10369
<210>4
<211>13535
<212>DNA
<213>仓鼠(Hamster sp.)
<220>
<221>misc_feature
<223>Seq.ID.No.1:环形质粒GS+IgG 2A热点导向载体pEE 15.1 hCMVp-GFP/克
隆11
<400>4
gaattcattg atcataatca gccataccac atttgtagag gttttacttg ctttaaaaaa 60
cctcccacac ctccccctga acctgaaaca taaaatgaat gcaattgttg ttgttaactt 120
gtttattgca gcttataatg gttacaaata aagcaatagc atcacaaatt tcacaaataa 180
agcatttttt tcactgcatt ctagttgtgg tttgtccaaa ctcatcaatg tatcttatca 240
tgtctggcgg ccgcgacctg caggcgcaga actggtaggt atggaagatc cctcgagatc 300
cattgtgctg gcggtaggcg agcagcgcct gcctgaagct gcgggcattc ccagtcagaa 360
atgagcgcca gtcgtcgtcg gctctcggca ccgaagtgct atgattctcc gccagcatgg 420
cttcggccag tgcgtcgagc agcgcccgct tgttcctgaa gtgccagtaa agcgccggct 480
gctgaacccc caaccgttcc gccagtttgc gtgtcgtcag accgtctacg ccgacctcgt 540
tcaacaggtc tagggcggca cggatcactg tattcggctg caactttgtc atgcttgaca 600
ctttatcact gataaacata atatgtccac caacttatca gtgataaaga atccgcgcca 660
gcacaatgga tctcgaggtc gagggatctc tagaggatcc atattcgcga atatgccggc 720
atcaccggcg ccacaggtgc ggttgctggc gcctatatcg ccgacatcac cgatggggaa 780
gatcgggctc gccacttcgg gctcatgagc gcttgtttcg gcgtgggtat ggtggcaggc 840
ccgtggccgg gggactgttg ggcgccatct ccttgcatgc accattcctt gcggcggcgg 900
tgctcaacgg cctcaaccta ctactgggct gcttcctaat gcaggagtcg cataagggag 960
agcgtcgagt cctccgtgtt cgaagcgatc cctgtccagt ggtgtgcaca ccttcccagc 1020
tgtcctgcag tctgacctct acaccctcag cagctcagtg actgtaacct cgagcacctg 1080
gcccagccag tccatcacct gcaatgtggc ccacccggca agcagcacca aggtggacaa 1140
gaaaattggt gaggaaaaca aggggagtag aggttcacaa gtgattagtc taaggcctta 1200
gcctagctag accagccagg atcagcagcc atcaccaaaa atgggaactt ggcccagaag 1260
agaaggagat actgactgtg actccctctt ggaaacttct aactatgacc acctaccttc 1320
aaggtcatga tcctctagga tagatgtcct tggtcatttc caggatcatc ctgacctaag 1380
gccataccca gggacaaagt ccctggtttg gtgccttttc tccttcaaac ttgagtaacc 1440
cccagccttc tctctgcaga gcccagaggg cccacaatca agccctgtcc tccatgcaaa 1500
tgcccaggta agtcactaga ccagagctcc acccgggaga atggtaagtg ctgtaaacat 1560
ccctgcacta gaggataagc catgtacaga tccatttcca tctctcctca tcagcaccta 1620
acctcttggg tggaccatcc gtcttcatct tccctccaaa gatcaaggat gtactcatga 1680
tctccctgag ccccatagtc acatgtgtgg tggtggatgt gagcgaggat gacccagatg 1740
tccagatcag ctggtttgtg aacaacgtgg aagtacacac agctcagaca caaacccata 1800
gagaggatta caacagtact ctccgggtgg tcagtgccct ccccatccag caccaggact 1860
ggatgagtgg caaggagttc aaatgcaagg tcaacaacaa agacctccca gcgcccatcg 1920
agagaaccat ctcaaaaccc aaaggtgaga gctgcagcct gactgcatgg gggctgggat 1980
gggcataagg ataaaggtct gtgtggacag ccttctgctt cagccatgac ctttgtgtat 2040
gtttctaccc tcacagggtc agtaagagct ccacaggtat atgtcttgcc tccaccagaa 2100
gaagagatga ctaagaaaca ggtcactctg acctgcatgg tcacagactt catgcctgaa 2160
gacatttacg tggagtggac caacaacggg aaaacagagc taaactacaa gaacactgaa 2220
ccagtcctgg actctgatgg ttcttacttc atgtacagca agctgagagt ggaaaagaag 2280
aactgggtgg aaagaaatag ctactcctgt tcagtggtcc acgagggtct gcacaatcac 2340
cacacgacta agagcttctc ccggactccg ggtaaatgag ctcagcaccc acaaaactct 2400
caggtccaaa gagacaccca cactcatctc catgcttccc ttgtataaat aaagcaccca 2460
ccaatgcctg ggaccatgta aaactgtcct ggttctttcc aaggtataga gcatagctca 2520
caggctgata tttctggcca gggttggagg acagccttgt ctataggaag agaatgaggt 2580
ttttgcactg caggactcag agctcattag ttatcctgcc ttggagtgtt ggggcttggc 2640
tttaggcagt gccttttcct tgccttccta cgaaccagca gctgccatac atagagataa 2700
tcctaggaag cctcaaatgg agaaggacac aaacccacct ccctcaggct gttcctctat 2760
cccggcccca cttctttacc taggggtttc tctgagtcta ttgtggagtt acacatggcc 2820
aggggcattc cagagaccct tgtcatccat acactcaact caggcagctt tgcacaaaca 2880
aagtctgcac acccatacag atggctcact cttgcctgtg ccatgtaggg ctgaggcaca 2940
tggctcttgc tgccccaagg gagggactat tagatagcca cactcatgct gaatcctggc 3000
ccattcaaat tagcctgctg aacaccatcc agtccatata gcacatgtat ccacatgcac 3060
gtgtgcacaa aacgcattta atacactggg acaacaattc tgtgccctgc acagcaccta 3120
tatccagcaa tgtatcacca tacacacgac caaaaaaatt caatgcccac gtttctgcca 3180
tcacaaacag acacatcttt cctctctgtg gccactgcat tatatgctca acacaagacc 3240
tctgaagcca gatccatctc tggcacctcg gggtcatgct tcaaccccac atgaattatg 3300
caaaccatag ccataatggt ctgaatcact tcacactggg atgttcccaa gttcaggcaa 3360
gacgagccac aggctctgct gatgactgaa ggacagcaaa gggtcagtcc agctgtatag 3420
ccactgttga cctgggtcac aggccctgct gaccctccac cttctcctgt actgaaggaa 3480
tgaaagatga gacaagcata gagggcactt gaataatcca ggtcactctg aggtccaccc 3540
aaggcattat tggactcagg tgggaagctg agactggtgt cccagaggga aaggaaggaa 3600
agcaggcccc ggggagggtc tgctgtccca gtcaggctgg agatctctcc tctgaatcca 3660
tgcagacatg tctgcctcac agggaatctc tcccagcacc aaccatgttg ggacaaacac 3720
tgactgtcct ctctgttcag ggctagacct ggatgatgtc tgtgctgagg cccaggacgg 3780
ggagctggac ggcctctgga cgaccatcac catcttcatc agcctcttcc tgctcagcgt 3840
gtgctacagc gcctctgtca cactcttcaa ggttggcact gtctcccacc ctctgctgtg 3900
atggctacac tgaccacaaa atgtcctctc actcctcccc agatgtagta ggacgttact 3960
ttgctgcccc tactctgtcc cacacaccat ttcctccatt ccctgagcca tcccacattg 4020
ttctatgtga ctccacattg tgtcccatac agtctgccct tctgtctctc tggctgtcct 4080
gcgtgatcct gatactgtct tatgagacca aacctccttg cattccacac tagccttcat 4140
gaggttcaat gctgtcttac acacaatccc ctcagcctca ccatggctca aggtactctg 4200
tgagctatcc tcataccatc tccacctcaa ctcccacaat atctccactc tgacccctcc 4260
catacccagt ctcctacctg tatgaaggga attgaaggag agacaggtcg acctctgtct 4320
ttcccacaga ttggagggtc tgagcatggg cgtggtctct gactttctct cacttcccca 4380
caggtaaagt ggatcttctc ctctgtggtg gagctgaagc agacgatctc ccctgactac 4440
agaaacatga ttgggcaggg agcctaggcc acttcctctg ggatcagaag agcttcctag 4500
gccctgcaga agcccatcca tcctactgtg cagcctaaca gggaggccac actctagccc 4560
tatgactctc tgatcagaac tcccatggtc tcctctttgg aggaccacgt gcagtgcagg 4620
ctttgcccag acctaaacac ttccacagca gtcgccagat atctaactac tccggaccag 4680
aagaaccatc tccttccaaa ccagcactag ggatctgaga tctcagaatg tttgcctaag 4740
aagagctgga aatccaggct tcctgtgttc tgctacaagg acatcagcct ggatttgacc 4800
tggaccacac attttcatct aaatgagttt tccacaaagg acacgtttca gatccttgaa 4860
tgagacctct acatggaaga ccagagtcac tatacccaaa ggtcactctg tatccttgca 4920
ccagctatac tggacagctt ccttcctggt acttcagtga ccctggctga ggaaaggatc 4980
tgtgacctca actgtttgga gagcctctgg aagatgtagt cttctcttcc tgctaccacc 5040
aacatgctgg atctcagatg cagaatccaa tccacagaca ccactgacca cacaacctga 5100
agacaaggcc attgccacct ccacagagat gccatccaca ctctgtggag aaataaggag 5160
tgctttgtgc agcctctgca aagctctggc agggattaga gtatacacac tgagtactga 5220
ctaggtgacc aggcagaaaa acctccagga gaaggaacaa tgggggagag atgtgaacag 5280
atagttagaa aaagcatggt gtcacaggtc tgctctgtgg actgatttcc agattggacc 5340
acctacagca gaaaccatcg gttgcagtgg caatctagga ggaccaacct ggaataggag 5400
ggctgctgtg gtcaatggag agtagacctg tatctatttc tccactgcct cttatgacca 5460
ataagaagcc agagtctcca gacagaaaga aagaaagaaa gaaagaaaga aagaaagaaa 5520
gaaagagaga gagagagaga gagagagaga gaggaaggaa ggaaggaagg aaggaaggaa 5580
ggaaggaagg aggaggagga ggaggaggag gaggaggaga gagagagaga gagagagaga 5640
gagagagaga gagcaccagc ttttctgtga ctggaaggaa atgcttagag agcttggatc 5700
tttaaagctt cttttttcta gagaccatga atgtctttgt tctctctctc tctctctctc 5760
tctctctctc tctctctctc tctctctgtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgcg 5820
tgcatgcacg ctattgtttt ggcatttgaa acaataaaac attcttttaa tattctgtat 5880
ctcatggttc cccttctgtg tggatcagcc ctaacaccca ggaacagggg acaataaaca 5940
gaccacagcc atgtacagcc ttctacctcc cttctggttc tgacctccca gaggtccctc 6000
agtgggcccc tcacagctgg gtttcttccc tggcagtgcc accaagagct caggcacctc 6060
tgagctggag gctgtcctga tgccataggc aggctatgga gcagagatga tgaccacggt 6120
ggactccagg tgagccaggc aaagcctccc atgccagaag agaagcgtgt ggtactcact 6180
ggcctcgggc tgctacggat tcagcaaaga gcatggatcg cttcgaagcc tccaagctcg 6240
acctcgggcc gcgttgctgg cgtttttcca taggctccgc ccccctgacg agcatcacaa 6300
aaatcgacgc tcaagtcaga ggtggcgaaa cccgacagga ctataaagat accaggcgtt 6360
tccccctgga agctccctcg tgcgctctcc tgttccgacc ctgccgctta ccggatacct 6420
gtccgccttt ctcccttcgg gaagcgtggc gctttctcaa tgctcacgct gtaggtatct 6480
cagttcggtg taggtcgttc gctccaagct gggctgtgtg cacgaacccc ccgttcagcc 6540
cgaccgctgc gccttatccg gtaactatcg tcttgagtcc aacccggtaa gacacgactt 6600
atcgccactg gcagcagcca ctggtaacag gattagcaga gcgaggtatg taggcggtgc 6660
tacagagttc ttgaagtggt ggcctaacta cggctacact agaaggacag tatttggtat 6720
ctgcgctctg ctgaagccag ttaccttcgg aaaaagagtt ggtagctctt gatccggcaa 6780
acaaaccacc gctggtagcg gtggtttttt tgtttgcaag cagcagatta cgcgcagaaa 6840
aaaaggatct caagaagatc ctttgatctt ttctacgggg tctgacgctc agtggaacga 6900
aaactcacgt taagggattt tggtcatgag attatcaaaa aggatcttca cctagatcct 6960
tttaaattaa aaatgaagtt ttaaatcaat ctaaagtata tatgagtaaa cttggtctga 7020
cagttaccaa tgcttaatca gtgaggcacc tatctcagcg atctgtctat ttcgttcatc 7080
catagttgcc tgactccccg tcgtgtagat aactacgata cgggagggct taccatctgg 7140
ccccagtgct gcaatgatac cgcgagaccc acgctcaccg gctccagatt tatcagcaat 7200
aaaccagcca gccggaaggg ccgagcgcag aagtggtcct gcaactttat ccgcctccat 7260
ccagtctatt aattgttgcc gggaagctag agtaagtagt tcgccagtta atagtttgcg 7320
caacgttgtt gccattgcta caggcatcgt ggtgtcacgc tcgtcgtttg gtatggcttc 7380
attcagctcc ggttcccaac gatcaaggcg agttacatga tcccccatgt tgtgcaaaaa 7440
agcggttagc tccttcggtc ctccgatcgt tgtcagaagt aagttggccg cagtgttatc 7500
actcatggtt atggcagcac tgcataattc tcttactgtc atgccatccg taagatgctt 7560
ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgtatgc ggcgaccgag 7620
ttgctcttgc ccggcgtcaa cacgggataa taccgcgcca catagcagaa ctttaaaagt 7680
gctcatcatt ggaaaacgtt cttcggggcg aaaactctca aggatcttac cgctgttgag 7740
atccagttcg atgtaaccca ctcgtgcacc caactgatct tcagcatctt ttactttcac 7800
cagcgtttct gggtgagcaa aaacaggaag gcaaaatgcc gcaaaaaagg gaataagggc 7860
gacacggaaa tgttgaatac tcatactctt cctttttcaa tattattgaa gcatttatca 7920
gggttattgt ctcatgagcg gatacatatt tgaatgtatt tagaaaaata aacaaatagg 7980
ggttccgcgc acatttcccc gaaaagtgcc acctgacgtc taagaaacca ttattatcat 8040
gacattaacc tataaaaata ggcgtatcac gaggccctga tggctctttg cggcacccat 8100
cgttcgtaat gttccgtggc accgaggaca accctcaaga gaaaatgtaa tcacactggc 8160
tcaccttcgg gtgggccttt ctgcgtttat aaggagacac tttatgttta agaaggttgg 8220
taaattcctt gcggctttgg cagccaagct agagatccgg ctgtggaatg tgtgtcagtt 8280
agggtgtgga aagtccccag gctccccagc aggcagaagt atgcaaagca tgcatctcaa 8340
ttagtcagca accaggtgtg gaaagtcccc aggctcccca gcaggcagaa gtatgcaaag 8400
catgcatctc aattagtcag caaccatagt cccgccccta actccgccca tcccgcccct 8460
aactccgccc agttccgccc attctccgcc ccatggctga ctaatttttt ttatttatgc 8520
agaggccgag gccgcctcgg cctctgagct attccagaag tagtgaggag gcttttttgg 8580
aggcctaggc ttttgcaaaa agctagcttg gggccaccgc tcagagcacc ttccaccatg 8640
gccacctcag caagttccca cttgaacaaa aacatcaagc aaatgtactt gtgcctgccc 8700
cagggtgaga aagtccaagc catgtatatc tgggttgatg gtactggaga aggactgcgc 8760
tgcaaaaccc gcaccctgga ctgtgagccc aagtgtgtag aagagttacc tgagtggaat 8820
tttgatggct ctagtacctt tcagtctgag ggctccaaca gtgacatgta tctcagccct 8880
gttgccatgt ttcgggaccc cttccgcaga gatcccaaca agctggtgtt ctgtgaagtt 8940
ttcaagtaca accggaagcc tgcagagacc aatttaaggc actcgtgtaa acggataatg 9000
gacatggtga gcaaccagca cccctggttt ggaatggaac aggagtatac tctgatggga 9060
acagatgggc acccttttgg ttggccttcc aatggctttc ctgggcccca aggtccgtat 9120
tactgtggtg tgggcgcaga caaagcctat ggcagggata tcgtggaggc tcactaccgc 9180
gcctgcttgt atgctggggt caagattaca ggaacaaatg ctgaggtcat gcctgcccag 9240
tgggaactcc aaataggacc ctgtgaagga atccgcatgg gagatcatct ctgggtggcc 9300
cgtttcatct tgcatcgagt atgtgaagac tttggggtaa tagcaacctt tgaccccaag 9360
cccattcctg ggaactggaa tggtgcaggc tgccatacca actttagcac caaggccatg 9420
cgggaggaga atggtctgaa gcacatcgag gaggccatcg agaaactaag caagcggcac 9480
cggtaccaca ttcgagccta cgatcccaag gggggcctgg acaatgcccg tggtctgact 9540
gggttccacg aaacgtccaa catcaacgac ttttctgctg gtgtcgccaa tcgcagtgcc 9600
agcatccgca ttccccggac tgtcggccag gagaagaaag gttactttga agaccgcggc 9660
ccctctgcca attgtgaccc ctttgcagtg acagaagcca tcgtccgcac atgccttctc 9720
aatgagactg gcgacgagcc cttccaatac aaaaactaat tagactttga gtgatcttga 9780
gcctttccta gttcatccca ccccgcccca gagagatctt tgtgaaggaa ccttacttct 9840
gtggtgtgac ataattggac aaactaccta cagagattta aagctctaag gtaaatataa 9900
aatttttaag tgtataatgt gttaaactac tgattctaat tgtttgtgta ttttagattc 9960
caacctatgg aactgatgaa tgggagcagt ggtggaatgc ctttaatgag gaaaacctgt 10020
tttgctcaga agaaatgcca tctagtgatg atgaggctac tgctgactct caacattcta 10080
ctcctccaaa aaagaagaga aaggtagaag accccaagga ctttccttca gaattgctaa 10140
gttttttgag tcatgctgtg tttagtaata gaactcttgc ttgctttgct atttacacca 10200
caaaggaaaa agctgcactg ctatacaaga aaattatgga aaaatattct gtaaccttta 10260
taagtaggca taacagttat aatcataaca tactgttttt tcttactcca cacaggcata 10320
gagtgtctgc tattaataac tatgctcaaa aattgtgtac ctttagcttt ttaatttgta 10380
aaggggttaa taaggaatat ttgatgtata gtgccttgac tagagatcat aatcagccat 10440
accacatttg tagaggtttt acttgcttta aaaaacctcc cacacctccc cctgaacctg 10500
aaacataaaa tgaatgcaat tgttgttgtt aacttgttta ttgcagctta taatggttac 10560
aaataaagca atagcatcac aaatttcaca aataaagcat ttttttcact gcattctagt 10620
tgtggtttgt ccaaactcat caatgtatct tatcatgtct ggatctctag cttcgtgtca 10680
aggacggtga ctgcagtgaa taataaaatg tgtgtttgtc cgaaatacgc gttttgagat 10740
ttctgtcgcc gactaaattc atgtcgcgcg atagtggtgt ttatcgccga tagagatggc 10800
gatattggaa aaatcgatat ttgaaaatat ggcatattga aaatgtcgcc gatgtgagtt 10860
tctgtgtaac tgatatcgcc atttttccaa aagtgatttt tgggcatacg cgatatctgg 10920
cgatagcgct tatatcgttt acgggggatg gcgatagacg actttggtga cttgggcgat 10980
tctgtgtgtc gcaaatatcg cagtttcgat ataggtgaca gacgatatga ggctatatcg 11040
ccgatagagg cgacatcaag ctggcacatg gccaatgcat atcgatctat acattgaatc 11100
aatattggcc attagccata ttattcattg gttatatagc ataaatcaat attggctatt 11160
ggccattgca tacgttgtat ccatatcata atatgtacat ttatattggc tcatgtccaa 11220
cattaccgcc atgttgacat tgattattga ctagttatta atagtaatca attacggggt 11280
cattagttca tagcccatat atggagttcc gcgttacata acttacggta aatggcccgc 11340
ctggctgacc gcccaacgac ccccgcccat tgacgtcaat aatgacgtat gttcccatag 11400
taacgccaat agggactttc cattgacgtc aatgggtgga gtatttacgg taaactgccc 11460
acttggcagt acatcaagtg tatcatatgc caagtacgcc ccctattgac gtcaatgacg 11520
gtaaatggcc cgcctggcat tatgcccagt acatgacctt atgggacttt cctacttggc 11580
agtacatcta cgtattagtc atcgctatta ccatggtgat gcggttttgg cagtacatca 11640
atgggcgtgg atagcggttt gactcacggg gatttccaag tctccacccc attgacgtca 11700
atgggagttt gttttggcac caaaatcaac gggactttcc aaaatgtcgt aacaactccg 11760
ccccattgac gcaaatgggc ggtaggcgtg tacggtggga ggtctatata agcagagctc 11820
gtttagtgaa ccgtcagatc gcctggagac gccatccacg ctgttttgac ctccatagaa 11880
gacaccggga ccgatccagc ctccgcggcc gggaacggtg cattggaacg cggattcccc 11940
gtgccaagag tgacgtaagt accgcctata gagtctatag gcccaccccc ttggcttctt 12000
atgcatgcta tactgttttt ggcttggggt ctatacaccc ccgcttcctc atgttatagg 12060
tgatggtata gcttagccta taggtgtggg ttattgacca ttattgacca ctcccctatt 12120
ggtgacgata ctttccatta ctaatccata acatggctct ttgccacaac tctctttatt 12180
ggctatatgc caatacactg tccttcagag actgacacgg actctgtatt tttacaggat 12240
ggggtctcat ttattattta caaattcaca tatacaacac caccgtcccc agtgcccgca 12300
gtttttatta aacataacgt gggatctcca cgcgaatctc gggtacgtgt tccggacatg 12360
ggctcttctc cggtagcggc ggagcttcta catccgagcc ctgctcccat gcctccagcg 12420
actcatggtc gctcggcagc tccttgctcc taacagtgga ggccagactt aggcacagca 12480
cgatgcccac caccaccagt gtgccgcaca aggccgtggc ggtagggtat gtgtctgaaa 12540
atgagctcgg ggagcgggct tgcaccgctg acgcatttgg aagacttaag gcagcggcag 12600
aagaagatgc aggcagctga gttgttgtgt tctgataaga gtcagaggta actcccgttg 12660
cggtgctgtt aacggtggag ggcagtgtag tctgagcagt actcgttgct gccgcgcgcg 12720
ccaccagaca taatagctga cagactaaca gactgttcct ttccatgggt cttttctgca 12780
gtcaccgtcc ttgacacgaa gcttgccgcc accatggtga gcaagcagat cctgaagaac 12840
accggcctgc aggagatcat gagcttcaag gtgaacctgg agggcgtggt gaacaaccac 12900
gtgttcacca tggagggctg cggcaagggc aacatcctgt tcggcaacca gctggtgcag 12960
atccgcgtga ccaagggcgc ccccctgccc ttcgccttcg acatcctgag ccccgccttc 13020
cagtacggca accgcacctt caccaagtac cccgaggaca tcagcgactt cttcatccag 13080
agcttccccg ccggcttcgt gtacgagcgc accctgcgct acgaggacgg cggcctggtg 13140
gagatccgca gcgacatcaa cctgatcgag gagatgttcg tgtaccgcgt ggagtacaag 13200
ggccgcaact tccccaacga cggccccgtg atgaagaaga ccatcaccgg cctgcagccc 13260
agcttcgagg tggtgtacat gaacgacggc gtgctggtgg gccaggtgat cctggtgtac 13320
cgcctgaaca gcggcaagtt ctacagctgc cacatgcgca ccctgatgaa gagcaagggc 13380
gtggtgaagg acttccccga gtaccacttc atccagcacc gcctggagaa gacctacgtg 13440
gaggacggcg gcttcgtgga gcagcacgag accgccatcg cccagctgac cagcctgggc 13500
aagcccctgg gcagcctgca cgagtgggtg taata 13535
Claims (8)
1.一种以表达载体转染的CHO细胞,所述表达载体包含在CHO细胞内具有活性并驱动重组产物蛋白表达的启动子和鼠IgG 2A基因座DNA内增强所述启动子活性部分。
2.如权利要求1所述的CHO细胞,所述载体还包含编码选择标记的转录单元,所述选择标记以谷氨酰胺合成酶标记为佳。
3.如权利要求1或2所述的CHO细胞,所述CHO细胞被稳定转染。
4.一种表达重组蛋白的方法,包括以下步骤:
c.培养以表达载体转染的CHO细胞,所述表达载体包含在CHO细胞内具有活性并驱动重组产物蛋白表达的启动子和鼠IgG 2A基因座DNA内增强所述启动子的活性的部分;
d.收获产物蛋白。
5.如权利要求4所述的方法,所述启动子是强病毒启动子,以hCMV启动子为佳。
6.如权利要求4或5所述的方法,所述IgG 2A基因座部分没有天然免疫球蛋白启动子。
7.一种哺乳动物表达载体,至少包括包含产物基因并受mCMV启动子调控的第一转录单元,还包括包含谷氨酰胺合成酶标记基因的第二转录单元。
8.用权利要求7所述载体转染的CHO细胞。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0216648.6A GB0216648D0 (en) | 2002-07-18 | 2002-07-18 | Method of expressing recombinant protein in CHO cells |
GB0216648.6 | 2002-07-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1668749A true CN1668749A (zh) | 2005-09-14 |
CN1296486C CN1296486C (zh) | 2007-01-24 |
Family
ID=9940670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB038169142A Expired - Lifetime CN1296486C (zh) | 2002-07-18 | 2003-07-21 | 在cho细胞内表达重组蛋白的方法 |
Country Status (14)
Country | Link |
---|---|
US (3) | US20060003405A1 (zh) |
EP (1) | EP1525320B1 (zh) |
CN (1) | CN1296486C (zh) |
AT (1) | ATE412761T1 (zh) |
AU (2) | AU2003251434B2 (zh) |
CA (2) | CA2489016C (zh) |
DE (1) | DE60324430D1 (zh) |
DK (1) | DK1525320T3 (zh) |
ES (1) | ES2314248T3 (zh) |
GB (1) | GB0216648D0 (zh) |
HK (1) | HK1081595A1 (zh) |
PT (1) | PT1525320E (zh) |
SI (1) | SI1525320T1 (zh) |
WO (1) | WO2004009823A1 (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104195173A (zh) * | 2014-09-02 | 2014-12-10 | 北京比洋生物技术有限公司 | 具有双表达盒的谷氨酰胺合成酶高效表达载体 |
CN104561091A (zh) * | 2014-12-17 | 2015-04-29 | 华南理工大学 | 一种光学分析检测cho细胞增殖的方法及应用 |
CN105779501A (zh) * | 2014-12-26 | 2016-07-20 | 上海药明康德新药开发有限公司 | 运用cho宿主细胞进行重组蛋白的瞬时表达生产的方法 |
CN105802995A (zh) * | 2014-12-31 | 2016-07-27 | 上海复宏汉霖生物技术有限公司 | 一种利用cho细胞生产重组蛋白的基因表达系统及真核表达载体 |
CN107881151A (zh) * | 2012-06-14 | 2018-04-06 | 赛诺菲 | Cho表达系统 |
CN107973841A (zh) * | 2016-12-23 | 2018-05-01 | 浙江海隆生物科技有限公司 | Cho细胞表达的重组牛病毒性腹泻病毒e2蛋白及亚单位疫苗的制备方法和应用 |
CN113005140A (zh) * | 2019-12-19 | 2021-06-22 | 鲁南制药集团股份有限公司 | 一种具有双表达盒的gs表达载体及其应用 |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0216648D0 (en) * | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
GB0319451D0 (en) * | 2003-08-19 | 2003-09-17 | Lonza Biologics Plc | Tropolone assay |
JP4809828B2 (ja) | 2004-03-30 | 2011-11-09 | グラクソ グループ リミテッド | 免疫グロブリン |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
JP2008536506A (ja) * | 2005-04-22 | 2008-09-11 | ロンザ・バイオロジクス・ピーエルシー | mCMVプロモーターおよびhCMV主要最初期遺伝子を含む哺乳類発現ベクター |
EP1915394B1 (en) * | 2005-05-20 | 2021-01-27 | Lonza Biologics plc. | High-level expression of recombinant antibody in a mammalian host cell |
JP4997239B2 (ja) | 2005-07-22 | 2012-08-08 | ワイズ・エー・シー株式会社 | 抗cd26抗体およびその使用方法 |
US9884899B2 (en) | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
US20090053786A1 (en) | 2007-07-09 | 2009-02-26 | Yung-Hsiang Kao | Prevention of disulfide bond reduction during recombinant production of polypeptides |
UY32341A (es) | 2008-12-19 | 2010-07-30 | Glaxo Group Ltd | Proteínas de unión antígeno novedosas |
CA2754961C (en) | 2009-03-11 | 2018-04-10 | Promedior, Inc. | Treatment and diagnostic methods for hypersensitive disorders |
JP5980508B2 (ja) | 2009-03-11 | 2016-08-31 | プロメディオール, インコーポレイテッド | 自己免疫障害に対する処置方法 |
UA110323C2 (en) | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
JP5822826B2 (ja) | 2009-06-17 | 2015-11-24 | プロメディオール, インコーポレイテッド | Sap変異体及びその使用 |
LT2464725T (lt) * | 2009-08-11 | 2020-06-10 | F. Hoffmann-La Roche Ag | Baltymų gamyba ląstelių mitybinėje terpėje, kurioje nėra glutamino |
WO2011080050A2 (en) | 2009-12-11 | 2011-07-07 | Novartis Ag | Binding molecules |
AU2011209713B2 (en) | 2010-01-28 | 2014-04-03 | Glaxo Group Limited | CD127 binding proteins |
UA123257C2 (uk) | 2010-02-24 | 2021-03-10 | Іммуноджен, Інк. | Виділений поліпептид, що кодує антитіло до рецептора фолієвої кислоти 1 |
UA108227C2 (xx) | 2010-03-03 | 2015-04-10 | Антигензв'язуючий білок | |
EP3620467A1 (en) | 2010-03-12 | 2020-03-11 | Debiopharm International SA | Cd37-binding molecules and immunoconjugates thereof |
UY33421A (es) | 2010-06-03 | 2011-12-30 | Glaxo Wellcome House | Proteinas de union al antígeno humanizados |
WO2012010635A1 (en) | 2010-07-22 | 2012-01-26 | Glaxosmithkline Biologicals S.A. | Novel antigen binding proteins |
WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
EP3357511B1 (en) | 2011-06-30 | 2020-05-13 | Genzyme Corporation | Inhibitors of t-cell activation |
CA2841745A1 (en) | 2011-07-15 | 2013-01-24 | Oncomed Pharmaceuticals, Inc. | Rspo binding agents and uses thereof |
US9549981B2 (en) | 2011-07-19 | 2017-01-24 | Philogen S.P.A. | Sequential antibody therapy |
UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
KR102091293B1 (ko) | 2011-09-23 | 2020-03-20 | 온코메드 파마슈티칼스, 인크. | Vegf/dll4 결합제 및 그의 용도 |
CN108424456B (zh) | 2011-11-23 | 2022-04-26 | 医学免疫有限责任公司 | 特异于her3的结合分子及其用途 |
JP2015520192A (ja) | 2012-06-06 | 2015-07-16 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Hippo経路を調節する結合剤およびその使用 |
KR20150036603A (ko) | 2012-07-13 | 2015-04-07 | 온코메드 파마슈티칼스, 인크. | Rspo3 결합제 및 그의 용도 |
NZ726258A (en) | 2012-08-31 | 2019-07-26 | Immunogen Inc | Antibodies and uses thereof to detect folate receptor 1 |
ES2540753T3 (es) | 2012-09-24 | 2015-07-13 | Lonza Biologics Plc. | Vectores de expresión que comprenden secuencias quiméricas de promotor y amplificador de citomegalovirus |
KR20150090919A (ko) | 2012-12-04 | 2015-08-06 | 온코메드 파마슈티칼스, 인크. | 결합제를 사용한 면역요법 |
WO2014100073A2 (en) * | 2012-12-21 | 2014-06-26 | Merck Sharp & Dohme Corp. | Expression vectors for recombinant protein production in mammalian cells |
SG10201907501QA (en) | 2013-08-30 | 2019-10-30 | Immunogen Inc | Antibodies and assays for detection of folate receptor 1 |
EP3069137A1 (en) | 2013-11-05 | 2016-09-21 | Novartis Ag | Organic compounds |
CN105829547A (zh) | 2013-12-02 | 2016-08-03 | 昂科梅德制药有限公司 | 与Wnt途径抑制剂有关的预测性生物标记物的鉴别 |
KR102489452B1 (ko) | 2014-02-02 | 2023-01-16 | 메디뮨 리미티드 | Ngf 길항제 도메인 및 tnfa 길항제 도메인으로 구성된 키메라 단백질 |
US8961992B1 (en) * | 2014-04-02 | 2015-02-24 | Tunitas Therapeutics, Inc. | Epsigam fusion protein |
PL3128997T3 (pl) | 2014-04-08 | 2020-12-28 | Boston Pharmaceuticals Inc. | Cząsteczki wiążące specyficznie il-21 i ich zastosowania |
KR20160143808A (ko) | 2014-04-11 | 2016-12-14 | 메디뮨 엘엘씨 | 이중특이적 her2 항체 |
WO2015165480A1 (en) | 2014-04-30 | 2015-11-05 | Institute For Research In Biomedicine | Human cytomegalovirus vaccine compositions and method of producing the same |
BR112016027845A2 (pt) | 2014-05-29 | 2017-10-31 | Medimmune Llc | proteínas de fusão de ox40l e usos das mesmas |
SG10201913406SA (en) * | 2014-07-18 | 2020-03-30 | Celltheon Corp | Methods and compositions for expression of polypeptides in a cell |
TW201619200A (zh) | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗-ox40抗體及其用途 |
WO2016059602A2 (en) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
CN107001472B (zh) | 2014-11-10 | 2020-12-11 | 免疫医疗有限公司 | 对cd73具有特异性的结合分子及其用途 |
GB2538120A (en) | 2014-11-11 | 2016-11-09 | Medimmune Ltd | Therapeutic combinations comprising anti-CD73 antibodies and uses thereof |
US10351630B2 (en) | 2015-01-09 | 2019-07-16 | Medimmune, Llc | Assay to detect human DPP-4 |
CA2985029A1 (en) | 2015-05-04 | 2016-11-10 | Vcn Biosciences Sl | Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment |
RU2739612C2 (ru) | 2015-06-29 | 2020-12-28 | Иммуноджен, Инк. | Анти-cd123 антитела и их конъюгаты и производные |
KR20180033588A (ko) | 2015-08-12 | 2018-04-03 | 메디뮨 리미티드 | Gitrl 융합 단백질 및 그의 용도 |
US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
CA3001364A1 (en) | 2015-10-09 | 2017-04-13 | Genzyme Corporation | Improved flare (flow cytometry attenuated reporter expression) technology for rapid bulk sorting |
AU2016352967A1 (en) | 2015-11-10 | 2018-06-21 | Medimmune, Llc | Binding molecules specific for ASCT2 and uses thereof |
KR20230152153A (ko) | 2016-03-10 | 2023-11-02 | 악셀레론 파마 인코포레이티드 | 액티빈 타입 2 수용체 결합 단백질 및 이의 용도 |
EP3426686A4 (en) | 2016-04-15 | 2019-11-06 | Alder Biopharmaceuticals, Inc. | HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF |
US20180126000A1 (en) | 2016-06-02 | 2018-05-10 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
SG11201903018WA (en) | 2016-10-07 | 2019-05-30 | Genzyme Corp | Early post-transfection isolation of cells (epic) for biologics production |
WO2018071345A1 (en) | 2016-10-11 | 2018-04-19 | Integrated Biotherapeutics, Inc. | Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop |
CA3044574A1 (en) | 2016-11-23 | 2018-05-31 | Bioverativ Therapeutics Inc. | Bispecific antibodies binding to coagulation factor ix and coagulation factor x |
JP7467119B2 (ja) | 2017-02-17 | 2024-04-15 | ロンザ リミテッド | 発現困難タンパク質のための多部位ssi細胞 |
GB201703418D0 (en) | 2017-03-03 | 2017-04-19 | Ge Healthcare Bio Sciences Ab | Method for cell line development |
CN110785494B (zh) | 2017-06-16 | 2024-07-02 | 隆萨有限公司 | 用于生产生物制品的通用自调节哺乳动物细胞系平台 |
KR20200095477A (ko) | 2017-12-01 | 2020-08-10 | 애브비 인코포레이티드 | 글루코코르티코이드 수용체 작용제 및 이의 면역접합체 |
EP3902824A4 (en) | 2018-12-28 | 2023-01-04 | Sparx Therapeutics Inc. | FOR CLAUDIN 18.2 SPECIFIC BINDING MOLECULES, COMPOSITIONS AND METHODS OF TREATMENT OF CANCER AND OTHER DISEASES |
AU2020253455A1 (en) | 2019-04-03 | 2021-11-04 | Genzyme Corporation | Anti-alpha beta TCR binding polypeptides with reduced fragmentation |
CA3144252A1 (en) | 2019-06-18 | 2020-12-24 | United Therapeutics Corporation | Mitochondrial treatment of organs for transplantation |
WO2021251340A1 (ja) | 2020-06-08 | 2021-12-16 | ワイズ・エー・シー株式会社 | 抗癌剤への抵抗性改善剤 |
CN117279942A (zh) | 2020-09-28 | 2023-12-22 | 免疫医疗有限公司 | 用于治疗疼痛的化合物和方法 |
JP2022184105A (ja) | 2021-05-31 | 2022-12-13 | ワイズ・エー・シー株式会社 | 抗cd26抗体と免疫チェックポイント阻害剤との併用療法 |
US11807685B2 (en) | 2021-08-05 | 2023-11-07 | The Uab Research Foundation | Anti-CD47 antibody and uses thereof |
CA3234162A1 (en) | 2021-10-15 | 2023-04-20 | Michele Fiscella | Antibodies and methods of using thereof |
WO2024062074A1 (en) | 2022-09-21 | 2024-03-28 | Sanofi Biotechnology | Humanized anti-il-1r3 antibody and methods of use |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2944850A1 (de) * | 1979-11-07 | 1981-05-27 | Bayer Ag, 5090 Leverkusen | Mittel zur regulierung des pflanzenwachstums, deren herstellung und deren verwendung |
US4968615A (en) * | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US4963481A (en) * | 1985-12-18 | 1990-10-16 | Genetics Institute Inc | Promoter system |
GB8601597D0 (en) * | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5891693A (en) * | 1990-01-25 | 1999-04-06 | Alusuisse Holdings A.G. | Recombinant DNA methods vectors and host cells |
IT1262545B (it) | 1993-10-25 | 1996-07-02 | Menarini Ricerche Sud S P A A | Sistema di espressione per linee cellulari eucariotiche |
DK0731845T3 (da) * | 1993-12-23 | 2003-10-20 | Merck & Co Inc | Homologt rekombinant antistofekspressionssystem til murine celler |
AU684134B2 (en) * | 1994-02-07 | 1997-12-04 | Qiagen Gmbh | Nucleic acid transfection efficiency increase by use of isopropanol in aqueous solutions |
GB0216648D0 (en) * | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
JP5171033B2 (ja) | 2003-03-11 | 2013-03-27 | メルク セローノ ソシエテ アノニム | mCMVIE2プロモーターを含んで成る発現ベクター |
-
2002
- 2002-07-18 GB GBGB0216648.6A patent/GB0216648D0/en not_active Ceased
-
2003
- 2003-07-21 DE DE60324430T patent/DE60324430D1/de not_active Expired - Lifetime
- 2003-07-21 AT AT03765075T patent/ATE412761T1/de active
- 2003-07-21 ES ES03765075T patent/ES2314248T3/es not_active Expired - Lifetime
- 2003-07-21 CN CNB038169142A patent/CN1296486C/zh not_active Expired - Lifetime
- 2003-07-21 SI SI200331477T patent/SI1525320T1/sl unknown
- 2003-07-21 WO PCT/EP2003/007946 patent/WO2004009823A1/en active Application Filing
- 2003-07-21 PT PT03765075T patent/PT1525320E/pt unknown
- 2003-07-21 US US10/521,768 patent/US20060003405A1/en not_active Abandoned
- 2003-07-21 AU AU2003251434A patent/AU2003251434B2/en not_active Expired
- 2003-07-21 EP EP03765075A patent/EP1525320B1/en not_active Expired - Lifetime
- 2003-07-21 DK DK03765075T patent/DK1525320T3/da active
- 2003-07-21 CA CA2489016A patent/CA2489016C/en not_active Expired - Lifetime
- 2003-07-21 CA CA2672809A patent/CA2672809C/en not_active Expired - Lifetime
-
2006
- 2006-02-10 HK HK06101786A patent/HK1081595A1/xx not_active IP Right Cessation
-
2007
- 2007-12-21 US US11/962,261 patent/US7932087B2/en not_active Expired - Lifetime
-
2009
- 2009-02-19 AU AU2009200665A patent/AU2009200665B2/en not_active Expired
-
2010
- 2010-12-10 US US12/964,918 patent/US20110104745A1/en not_active Abandoned
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107881151A (zh) * | 2012-06-14 | 2018-04-06 | 赛诺菲 | Cho表达系统 |
CN104195173A (zh) * | 2014-09-02 | 2014-12-10 | 北京比洋生物技术有限公司 | 具有双表达盒的谷氨酰胺合成酶高效表达载体 |
CN104561091A (zh) * | 2014-12-17 | 2015-04-29 | 华南理工大学 | 一种光学分析检测cho细胞增殖的方法及应用 |
CN105779501A (zh) * | 2014-12-26 | 2016-07-20 | 上海药明康德新药开发有限公司 | 运用cho宿主细胞进行重组蛋白的瞬时表达生产的方法 |
CN105802995A (zh) * | 2014-12-31 | 2016-07-27 | 上海复宏汉霖生物技术有限公司 | 一种利用cho细胞生产重组蛋白的基因表达系统及真核表达载体 |
CN107973841A (zh) * | 2016-12-23 | 2018-05-01 | 浙江海隆生物科技有限公司 | Cho细胞表达的重组牛病毒性腹泻病毒e2蛋白及亚单位疫苗的制备方法和应用 |
CN113005140A (zh) * | 2019-12-19 | 2021-06-22 | 鲁南制药集团股份有限公司 | 一种具有双表达盒的gs表达载体及其应用 |
CN113005140B (zh) * | 2019-12-19 | 2024-03-15 | 鲁南制药集团股份有限公司 | 一种具有双表达盒的gs表达载体及其应用 |
Also Published As
Publication number | Publication date |
---|---|
DE60324430D1 (de) | 2008-12-11 |
CA2489016C (en) | 2012-01-17 |
AU2003251434A1 (en) | 2004-02-09 |
CA2672809C (en) | 2013-01-08 |
EP1525320A1 (en) | 2005-04-27 |
DK1525320T3 (da) | 2009-02-23 |
GB0216648D0 (en) | 2002-08-28 |
CN1296486C (zh) | 2007-01-24 |
SI1525320T1 (sl) | 2009-02-28 |
HK1081595A1 (en) | 2006-05-19 |
CA2672809A1 (en) | 2004-01-29 |
US20060003405A1 (en) | 2006-01-05 |
US20110104745A1 (en) | 2011-05-05 |
EP1525320B1 (en) | 2008-10-29 |
AU2003251434B2 (en) | 2009-03-05 |
CA2489016A1 (en) | 2004-01-29 |
PT1525320E (pt) | 2009-01-23 |
US20080138902A1 (en) | 2008-06-12 |
ATE412761T1 (de) | 2008-11-15 |
AU2009200665B2 (en) | 2012-08-16 |
WO2004009823A1 (en) | 2004-01-29 |
ES2314248T3 (es) | 2009-03-16 |
US7932087B2 (en) | 2011-04-26 |
AU2009200665A1 (en) | 2009-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1296486C (zh) | 在cho细胞内表达重组蛋白的方法 | |
US11186847B2 (en) | Minimal piggyBac vectors for genome integration | |
CN1890373A (zh) | Dna克隆载体质粒及其使用方法 | |
CN1628169A (zh) | 含人抗体λ轻链基因的人类人工染色体 | |
CN1232644C (zh) | 细胞内生基因活性化的优化方法 | |
CN1533432A (zh) | 高水平、大规模生产重组蛋白的组合体和方法 | |
CN1461343A (zh) | 多核苷酸 | |
JP2024083457A (ja) | レンチウイルスベクターのバイオ生産法 | |
CN1774500A (zh) | 用于瞬时或稳定表达外源分子的表达盒和载体 | |
KR20210049133A (ko) | 무혈청 배지에서 벡터 제조 | |
CA2880750A1 (en) | Expression vectors comprising chimeric cytomegalovirus promoter and enhancer sequences | |
CN1902318A (zh) | 细菌宿主细胞中稳定地基因扩增的方法 | |
CN116348607A (zh) | 用于同时基因活化的核酸构建体 | |
CN1771324A (zh) | 动物细胞用高表达载体 | |
KR100976098B1 (ko) | Cho 세포에서 재조합 단백질의 발현 방법 | |
JP5209693B2 (ja) | Cho細胞において組換えタンパク質を発現する方法 | |
CN100340667C (zh) | 用于rna干扰研究的表达载体 | |
CN1717489A (zh) | 真核细胞中的序列特异性dna重组 | |
JP4430535B2 (ja) | Cho細胞において組換えタンパク質を発現する方法 | |
CN1370240A (zh) | 利用ppar核受体的表达调节系统 | |
JP5502406B2 (ja) | Cho細胞において組換えタンパク質を発現する方法 | |
CN1646906A (zh) | Redk基因的破坏 | |
CN1643142A (zh) | 鉴定控制分化的基因的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1081595 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20070124 |